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iINTRODUCTION
One Sunday morning earlier this year, I was offered a potent and disturbing reminder
of current trends in childhood asthma. Our one-year-old son, Conall, had developed
a loud expiratory wheeze and persistent nocturnal cough following a series of
debilitating upper respiratory tract infections and, perhaps significantly, coinciding
with the extremely high pollen counts recorded that month. We had attempted to
relieve the symptoms with a salbutamol inhaler delivered through a spacer and mask
but to no effect. That morning, he began exhibiting signs of severe respiratory distress
and I took him to the accident and emergency department in the small local hospital.
He was given nebulized salbutamol which immediately eased both his (and my)
distress and the wheeze, he was prescribed a short course of oral steroids and a follow-
up steroid inhaler, and we were advised to see our GP later that week. 
Of course, our experience was by no means unusual. We all know families where
young children suffer recurrent episodes of wheezing and nocturnal coughing, and
where the use of both β-agonist and steroid inhalers is commonplace. When we lived
in Manchester, where our older son, Riordan, first developed symptoms of asthma
three or four years ago, our GP was insistent that the number of wheezy children seen
in her surgery had increased dramatically over the previous ten years, particularly in
those areas of Manchester close to major roads. Indeed, when we moved from
Manchester to Exeter in 1998, one of our hopes was that fresh sea breezes drifting
along the south-west coast, which had been renowned as a respiratory resort during
the late nineteenth century, would afford our son some relief. Although such attempts
at geographical or climatic management of asthma and hay fever have numerous
historical precedents,1 they are not always successful. In the modern world, asthma in
children and adults is clearly not merely an urban disease. The receptionist at the
school in Exmouth currently attended by our two older children, for example, is
inundated with different coloured inhalers to be given to various children at various
times. And if we are to believe the media, in the last decade of the twentieth century
an ‘inhaler culture’ has emerged in playgrounds around the country. 
Significantly, such anecdotal stories of the modern increase in wheezing and asthma in
children are supported by epidemiological evidence. Recent research has clearly
demonstrated not only a prominent rise in the incidence and prevalence of asthma in all
age-groups worldwide, but also, at least until very recently, a rising mortality rate.2 As
both the levels and severity of asthma in the general population rose in the last decades
of the twentieth century, asthma emerged as a major clinical, public health, and
socioeconomic concern. Hospital admissions for asthma have risen, partly in response to
1 See, for example, Walshe W H. (1871) A Practical Treatise on the Diseases of the Lungs: Including the principles of
physical diagnosis, and notes on climate. London: James Walton.
2 Chadwick D, Cardew G. (eds) (1997)The Rising Trends in Asthma. Ciba Foundation Symposium 206. Chichester:
John Wiley and Sons.
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rising levels of morbidity and mortality from asthma, and partly as the result of changing
hospital admission policies (such as self-referral), greater GP awareness, and the
introduction of novel practices (such as asthma clinics) during the 1980s and 1990s. The
current cost of treating 3.4 million asthmatics in the UK is estimated at £23 million –
a figure that includes physician time, and the cost of hospitalization and medication. 
One of the paradoxes of modern asthma is that such trends in incidence, prevalence,
and severity have occurred at precisely the time when treatment options have
improved significantly. As contributors to this Witness Seminar make clear in their
testimony, during the last half of the twentieth century there were dramatic
developments both in the symptomatic relief of wheezing and in the organization of
asthma services: the introduction of selective β-agonists such as salbutamol by Allen
and Hanburys in the late 1960s; the development of sodium cromoglycate around the
same time; the availability of inhaled corticosteroids from the early 1970s; the
expansion of asthma clinics and asthma nurses from the 1980s; and the growing
educational role of organizations such as the National Asthma Campaign, formerly
the Asthma Research Council, established in 1927 as a means of promoting and
funding clinical research. As evidence presented to this seminar also demonstrates,
these developments owed a great deal to the persistent visionary zeal of innovators and
motivators such as Roger Altounyan, Sir David Jack, Greta Barnes, and many others.
It is important to remember, however, that while pharmaceutical developments in
particular have dominated recent approaches to asthma management, other strategies,
mentioned only in passing in the seminar, have also played a major role in the history
of childhood asthma. First, it is important to recognize that until concerns about its
safety emerged in the 1980s, allergen immunotherapy was an approach to asthma
favoured by many allergists (pages 44–45, 50). Initially introduced for the treatment
of hay fever by John Freeman and Leonard Noon in 1911, immunotherapy or
desensitization for asthma, hay fever, and bee stings in particular became the
cornerstone of clinical allergy in the middle decades of the twentieth century. Its
practice in the UK was dramatically curtailed by the controversial intervention of the
Committee on Safety of Medicines in 1986, after reports of deaths in asthmatics
following the procedure, although its role is currently being re-evaluated.3
Secondly, while Professor Godfrey refers to the role of Alpine schools for Italian
asthmatic children (page 47), we should remember that open-air schools also played
a crucial role in the treatment of asthmatic children in this country. First developed
for the treatment of tuberculous children in the early years of the twentieth century,4
3 For a discussion of the history of immunotherapy, see Jackson M. (2001) Between scepticism and wild
enthusiasm: the chequered history of allergen immunotherapy in Britain, in Moulin A M, Cambrosio A. (eds)
Singular Selves: Historical issues and contemporary debates in immunology. Amsterdam: Elsevier, 155–164.
4 Bryder, L. (1992) ‘Wonderlands of buttercup, clover and daisies’: tuberculosis and the open-air school movement
in Britain, 1907–39, in Cooter R. (ed.) In the Name of the Child: Health and welfare, 1880–1940. London:
Routledge, 72–95.
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open-air schools were increasingly used to treat a variety of other respiratory
conditions, including asthma and bronchitis, at least until the introduction of more
effective medication in the 1960s. In Birmingham, for example, the schools at
Uffculme and Cropwood regularly admitted children with asthma, and routinely sent
children abroad to the Davos Alpine School in Switzerland.5 Of course, open air was
only one part of the therapeutic regime. The children also received better nutrition
and more exercise and, according to some commentators, benefited from being
removed from both their home environment and their parents. The adoption and
demise of ‘parentectomy’, which proved popular on both sides of the Atlantic in the
middle decades of the century, would be worthy of more extensive historical study.
While the startling rise in asthma in the face of improvements in treatment
constitutes one paradox in the history of the disease, there are many other
complexities and ambiguities to be considered. First, it is not entirely clear to what
extent the current epidemic of asthma is the product of changing definitions and
shifting diagnostic labels. It has often proved difficult to define the precise
functional and pathophysiological features that differentiate asthma from other
chronic obstructive lung diseases.6 In addition, it is evident that during the late
1960s and 1970s, doctors increasingly labelled as asthmatic children who previously
would have been diagnosed as having ‘wheezy bronchitis’ (page 61).7 Such
diagnostic shifts, accentuated by contrasting national approaches to classification
and the elaboration of diagnostic criteria, have made epidemiological
generalizations more problematic.
Secondly, while much is known about the epidemiology of asthma, it remains difficult
to account precisely either for recent rises in asthma morbidity at a population level
or for exacerbations in individual patients. Changing diet, carpets, double-glazing,
central heating, the rise in allergies, maternal smoking, changing family size, improved
standards of hygiene, medication, industrial and traffic-related pollution, and other
factors have all been implicated in modern trends in childhood asthma, eczema, and
hay fever. While many of these factors may operate at an epidemiological level, it is
not always apparent precisely what triggers the development of asthma or the
occurrence of an attack in a particular child. It is also important to remember that
debates about the causes of recent trends in asthma have become deeply political,
firmly shaped by millennial anxieties about controlling both the domestic and
outdoor environments, shifting notions of individual and state responsibility for
5 Wilmot F, Saul P. (1998) A Breath of Fresh Air: Birmingham’s open-air schools 1911–1970. Chichester: Phillimore.
6 The classification and differential diagnosis of chronic respiratory diseases proved a prominent focus for
international conferences particularly during the 1950s and 1960s. See Ciba Symposium Report (1959)
Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions. Thorax 14:
286–299. Scadding J G. (1963) Meaning of diagnostic terms in broncho-pulmonary disease. British Medical
Journal ii: 1425–1430.
7 Pereira Gray D J. (1980) Gale memorial lecture 1979: Just a GP. Journal of the Royal College of General
Practitioners 30: 231–239.
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healthcare, and concerns about the detrimental effects of modern civilization,
including modern medicine.
Finally, there remain tense debates about the involvement of allergy (or more
accurately, atopy) in asthma (page 47) and about the importance of psychological
factors in triggering attacks. In the late nineteenth and early twentieth centuries,
asthma was commonly understood to be neurogenic, that is the product of
imbalances in the nervous system. With the development of more sophisticated
studies of the immunology and biochemistry of allergic reactions and of the
pathogenesis of asthma, neurological and psychogenic theories of asthma fell into
disrepute. They generally surfaced only in marginal or alternative approaches to
treatment, shaped largely by psychoanalytical concepts of the mind–body
relationship.8 In recent years, however, the contribution of the mind has once again
become a focus, both for scientists interested in the interplay between mental
processes and the nervous, immunological and endocrine systems, and for
clinicians keen to reduce reliance on medication and improve patients’ own control
of their symptoms.
Unfortunately, in spite of evident clinical, scientific, epidemiological, political and
media interest in asthma, there have been few studies of its history in either adults or
children. Apart from some useful overviews by Alex Sakula, the marvellous collection
of classic papers edited with an introduction by Alistair Brewis,9 and the on-going
research of Ian Gregg into mortality figures and hospital admissions, asthma (like
many chronic conditions) has figured only rarely in recent histories of medicine.10 At
the turn of the millennium, when allergic diseases, including asthma, appear to have
reached epidemic proportions, the time is ripe for closer historical scrutiny of asthma
in a manner that effectively incorporates and integrates the work of historians,
epidemiologists, immunologists, and clinicians. 
We should be grateful to Dr Chris O’Callaghan and Dr Daphne Christie and to the
Wellcome Trust’s History of Twentieth Century Medicine Group for beginning the
process of historical reconstruction so energetically by organizing this Witness
Seminar ‘Childhood Asthma and Beyond’, and to Dr Tilli Tansey and Mrs Lois
Reynolds for its conversion into print. Chaired with considerable insight, enthusiasm,
and humour by Professor Simon Godfrey, the contributions to the discussion from
leading figures in the fight against asthma shed light on many crucial issues in the
history of asthma, notably the discovery and development of new pharmaceutical
8 See Kimball C P. (1970) Conceptual developments in psychosomatic medicine: 1939–1969. Annals of Internal
Medicine 73: 307–316. Inglis B. (1981) The Diseases of Civilization. London: Hodder and Stoughton, 218–226.
9 See transcript notes 7 and 11.
10 For some historical articles, see Keeney E L. (1964) The history of asthma from Hippocrates to Meltzer. Journal of
Allergy 35: 215–226. Sakula A. (1988) A history of asthma: The Fitzpatrick Lecture 1987. Transactions of the Royal
College of Physicians 22: 36–44. Emanuel M B, Howarth P H. (1995) Asthma and anaphylaxis: a relevant model for
chronic disease? An historical analysis of directions in asthma research. Clinical and Experimental Allergy 25: 15–26. 
11 For further information on asthma mortality statistics and hospital admission rates, see the excellent Factsheets,
published regularly by the Lung and Asthma Information Agency in the Department of Public Health Sciences at St
George’s Hospital Medical School, London, or visit their website (www.sghms.ac.uk/depts/laia/laia.htm; visited 30
July 2001). Regular updates on asthma statistics are also available from the National Asthma Campaign, either
through their subscription newsletter, Asthma News, or via their website (www.asthma.org.uk; visited 30 July 2001). 
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agents in the 1960s and 1970s, and, perhaps more interesting from a social history
perspective, the emergence of a new culture of disease surveillance and healthcare
provision with the establishment of asthma clinics and the training of specialist
asthma nurses from the 1980s. More broadly, the range of questions raised as well as
answered during the seminar should remind us of the nature and complexity of the
challenges faced by both historians and clinicians in their quest to understand the
causes of modern trends in asthma.11
Mark Jackson
University of Exeter
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1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth Century
Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of Medicine at
University College London.
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In 1990 the Wellcome Trust created a History of Twentieth Century Medicine Group,
as part of the Academic Unit of the Wellcome Institute for the History of Medicine,
to bring together clinicians, scientists, historians and others interested in
contemporary medical history. Among a number of other initiatives the format of
Witness Seminars, used by the Institute of Contemporary British History to address
issues of recent political history, was adopted, to promote interaction between these
different groups, to emphasize the potential of working jointly, and to encourage the
creation and deposit of archival sources for present and future use. In June 1999 the
Governors of the Wellcome Trust decided that it would be appropriate for the
Academic Unit to enjoy a more formal academic affiliation and turned the Unit into
the Wellcome Trust Centre for the History of Medicine at University College London
from 1 October 2000. The Wellcome Trust continues to fund the Witness Seminar
programme via its support for the Centre.
The Witness Seminar is a particularly specialized form of oral history where several
people associated with a particular set of circumstances or events are invited to meet
together to discuss, debate, and agree or disagree about their memories. To date, the
History of Twentieth Century Medicine Group has held over 25 such meetings, most
of which have been published, as listed in the table on page viii.
Subjects for such meetings are usually proposed by, or through, members of the
Programme Committee of the Group, and once an appropriate topic has been agreed,
suitable participants are identified and invited. These inevitably lead to further contacts,
and more suggestions of people to invite. As the organization of the meeting progresses,
a flexible outline plan for the meeting is devised, usually with assistance from the
meeting’s chairman, and some participants are invited to ‘set the ball rolling’ on particular
themes, by speaking for a short period of time to initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited transcript
is immediately sent to every participant. Each is asked to check their own
contributions and to provide brief biographical details. The editors turn the transcript
into readable text, and participants’ minor corrections and comments are
incorporated into that text, while biographical and bibliographical details are added
as footnotes, as are more substantial comments and additional material provided by
participants. The final scripts are then sent to every contributor, accompanied by
forms assigning copyright to the Wellcome Trust. Copies of all additional
correspondence received during the editorial process are deposited with the records of
each meeting in Archives and Manuscripts, Wellcome Library, London. 
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As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the nonspecialist, the sense and significance of the
events are understandable. Our aim is for the volumes that emerge from these meetings
to inform those with a general interest in the history of modern medicine and medical
science; to provide historians with new insights, fresh material for study, and further
themes for research; and to emphasize to the participants that events of the recent past,
of their own working lives, are of proper and necessary concern to historians.
Members of the Programme Committee of the 
History of Twentieth Century Medicine Group
The Group’s activities are overseen by the Programme Committee, which includes
professional historians of medicine, practising scientists and clinicians. The Programme
Committee during 2000–01 comprised:
Dr Tilli Tansey – Historian of Modern Medical Science, Wellcome Trust Centre at UCL,
and Chairman
Sir Christopher Booth – Wellcome Trust Centre at UCL, former Director, Clinical Research
Centre, Northwick Park Hospital, London
Dr Robert Bud – Head of Life and Environmental Sciences, Science Museum, London
Dr Daphne Christie – Senior Research Assistant, Wellcome Trust Centre at UCL and
Organizing Secretary
Dr Gordon Cook – Wellcome Trust Centre at UCL, former consultant, Hospital for Tropical
Diseases, London
Professor Hal Cook – Director, Wellcome Trust Centre at UCL
Professor Chris O’Callaghan – Consultant Paediatrician, Leicester
Dr Jon Turney – Head of the Department of Science and Technology Studies, University
College London.
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Professor Chris O’Callaghan:1 I am a paediatrician from Leicester, and have been
asked to introduce this Witness Seminar on the history of childhood asthma. This
meeting has been organized by the History of Twentieth Century Medicine Group at
the Wellcome Trust. The group was established to promote interaction between
clinicians, scientists, and historians interested in modern medical history. The
Programme Committee of the group led by Dr Tilli Tansey decides on the
programme. Dr Daphne Christie has been instrumental in the organization of this
meeting. The seminars are intended to stimulate debate and discussion of events in
contemporary medical history between scientists and historians. The meeting is being
taped and it is very important that you say your name every time you speak to aid the
transcriber. You may say what you want, as your permission will be required before
publication. The tapes will be archived.2
It gives me great pleasure to introduce Professor Simon Godfrey, who is now Professor
of Paediatrics and Director of the Institute of Pulmonology at Hadassah University
Hospital in Jerusalem. Simon has been a leader in this field for many years. He saw many
of the major developments in childhood asthma while working at the Hammersmith
and the Brompton Hospitals, London, and was instrumental in some of them.
Professor Simon Godfrey:3 Chris, thank you very much. First of all I must thank the
Wellcome Trust for organizing this Witness Seminar and for inviting me along to
chair. I discussed this at length with friends and family to know whether this was a
great honour to be asked, or whether they asked me to do it because they reckoned I
was the most senile person around, just compos mentis enough to do it. But that we
will see as time goes by, but it really is a pleasure to be here and it’s wonderful to see
so many of you – friends and teachers, my teachers – here. I am delighted to see them
here and I hope we are going to hear from them. I think we all know about what has
happened from 1960 to now, but I personally think it is going to be very interesting
to hear people reminisce about what happened from 1900 to 1960. This seminar is
1 Professor Chris O’Callaghan (b. 1959) has been Professor of Paediatrics at the Department of Child Health and
Institute of Lung Health, University of Leicester, since October 2000 and had been Senior Lecturer and
Consultant Paediatrician at the University of Leicester. He has been a member of the Wellcome Trust’s History of
Twentieth Century Medicine Group Programme Committee from 1998 to 2001, following a Wellcome Trust
Short-term Leave Fellowship in the History of Medicine for Clinicians and Scientists from June to October 1997
researching the history of metered dose inhalers. 
2 Many participants provided additional material for their contributions in more detail than can be included here,
but all correspondence related to this meeting is deposited, along with tapes, and other records received during the
editorial process, in Archives and Manuscripts, Wellcome Library, London.
3 Professor Simon Godfrey FRCP FRCPCH (b. 1939) qualified at the London Hospital Medical College in 1962,
undertook further research and obtained his PhD and later his MD from the University of London. He worked
chiefly at the Hammersmith and Royal Brompton Hospitals in London from 1963. In 1977 he moved to
Jerusalem as Professor of Paediatrics at the Hadassah University Hospital and in 1991 was appointed Director of
the Institute of Pulmonology. 
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intended to be informal. People are invited to join in and make comments. There are
one or two people who have been volunteered to say things at various points, but
please, the idea is that you all join in and have as much fun as you can and reminisce
or make your comments. I think it will be nice not to be too litigious or whatever the
word might be in discussing various controversial issues, but I think we can carry on
in a friendly atmosphere. Now I thought I would just start the ball rolling by quoting
something not from the twentieth century, but from the twelfth century and I imagine
there is only one other person in this room, maybe two, who will be able to tell me
afterwards where it came from, and it goes like this: 
‘in this aphorism it is my purpose to bring before you something well
deserving your examination and belief. If anyone declares to you that he has
actual proof from his own experience of something of which he requires for
the confirmation of his theory, even though he is considered a man of great
authority, truthfulness, earnest words and morality, yet just because he is
anxious for you to believe his theory, you should hesitate’.4
Now I like that, although that was not Karl Popper,5 beloved of my teacher Moran
Campbell,6 and I imagine many others here, but it was in fact Maimonides who was
born in 1135 and died in 1204. He was a philosopher, a rabbi, and a physician, and
I think that’s absolutely wonderful, because of course it is what Karl Popper and
scientific philosophers of our own day are saying. Just because you say something
forcefully, doesn’t necessarily mean it is correct, and I think it will be interesting today
to hear what people remember of others saying something forcefully that has not
proved to be correct, and perhaps also some of the things that have been proved to be
correct. With that little introduction, I would like to ask Chris [O’Callaghan] to give
a formal historical background for the Witness Seminar.
O’Callaghan: This is just very brief and hopefully brings us up to the beginning of the
last century. We don’t really know when man first developed asthma. Descriptions of
the disease date back well over 3000 years and various rather strange remedies were
given. The ancient Egyptians used enemas and camel and crocodile dung to treat their
patients. The ancient Greeks and Romans also recognized the disease and it was the
blind poet Homer who first coined the term ‘asthma’ which, as we know, is the Greek
word for panting [ασθµα]. Little progress was made in the treatment or knowledge of
4 Moses Maimonides (1135–1204) was court physician to the Sultan Saladin, whose son suffered from asthma. For
a review of his work see Rosner R. (1981) Moses Maimonides’ Treatise on Asthma. Thorax 36: 245–251.
5 Sir Karl Popper (1902–1994) was a British philosopher of science, born in Austria. See Popper K. (1945) The
Open Society and its Enemies, 2 vols. London: Routledge. Susser M. (1986) The logic of Sir Karl Popper and the
practice of epidemiology. American Journal of Epidemiology 124: 711–718. See also Medawar P. (1977) The
philosophy of Karl Popper, in Pyke D. (ed.) (1991) The Threat and the Glory: Reflections on science and scientists.
Oxford: Oxford University Press, 91–101.
6 Dr Edward James Moran Campbell (b. 1928) held the founding chair of the Department of Medicine at the
University of McMaster, Hamilton, Ontario, Canada, from 1968 to 1975 and was an internationally renowned
researcher in diseases of the lung. See Campbell E J M. (1988) Not Always on the Level. Cambridge: Cambridge
University Press for the Memoir Club.
Childhood Asthma and Beyond
5
asthma until the twelfth century, when Moses Maimonides wrote a really excellent
work on asthma in relation to the asthmatic son of the Sultan Saladin. His treatment
advice was to avoid emotional turmoil, sexual activity, and he recommended chicken
soup [‘Jewish penicillin’] as a recipe. I guess chicken soup is quite safe.
Godfrey: I think it was excessive sexual activity, actually.
O’Callaghan: It’s obviously been modified over the years. It’s interesting that many of
the best descriptions were by doctors who had the disease themselves. Sir John Floyer,7
an eminent doctor, was an asthma sufferer and the first to differentiate the condition
from other types of dyspnoea. Floyer recognized that there were several factors
underlying the asthmatic state and he described these in the 1700s as heredity, weather,
seasons and atmospheric pollution, including tobacco, occupational influences, personal
idiosyncrasies and emotions. He also recognized the importance of nocturnal asthma. 
It was in 1808 when Reisseissen of Strasbourg8 demonstrated that the bronchial wall
contained a distinct layer of muscle fibre, which when contracted led to constriction of
the airways. This finding was exploited by Laënnec,9 a brilliant French physician, who
clarified the nature and diagnosis of asthma by physical examination of the thorax,
using the stethoscope that he had invented. The foremost authority on asthma during
the nineteenth century was Henry Hyde Salter,10 who described bronchial hyper-
reactivity and recommended stramonium11 and strong coffee. A clear description of the
disease was given, again probably based on the fact that he himself had severe asthma. 
In terms of drug therapy, it was in 1900 when Solomon Solis-Cohen12 injected crude
adrenal extracts into patients with asthma or hay fever. Shortly afterwards Jessie
Bullowa and David Kaplan13 reported successful adrenaline injections that took over
7 Sir John Floyer (1649–1734) was a physician, living in Lichfield. See Sakula A. (1984) Sir John Floyer’s ‘A treatise
of the asthma’ (1698). Thorax 39: 248–254. For a facsimile version of the paper, see Brewis R A L. (ed.) (1990)
Classic Papers in Asthma. Volume 1: The evolution of understanding. London: Science Press, 30–52.
8 Reisseissen F D. (1808) Ueber den Bau der Lungen. Berlin: Rucker. 
9 René Théophile Hyacinthe Laënnec (1781–1826) invented the stethoscope. See Laënnec R T H. (1819)
L’auscultation mediate, reproduced as a facsimile copy in Brewis R A L. (ed.) (1990), note 7, 84–100. 
10 Salter H H. (1860) On Asthma: Its pathology and treatment. London: John Churchill. For a facsimile copy of
Chapter 2, see Brewis R A L. (ed.) (1990), note 7, 106–142. For example, see also Cohen S G. (1997) Asthma
among the famous: Henry Hyde Salter (1823–1871), British physician. Allergy and Asthma Proceedings 18:
256–258. Neale A V. (1963) Some thoughts and experiments on respiration and on asthma, with special reference
to Henry Hyde Salter. Medical History 7: 247–257.
11 Stramonium is derived from the poisonous Datura stramonium or jimson weed. In minute doses, administered
internally or by inhaled smoke, it acts as an antispasmodic giving temporary relief in asthma. See Sims J. (1812)
Communications relative to the Datura stramonium, or thorn apple: as a cure or relief of asthma. Edinburgh
Medical and Surgical Journal 8: 364–367. See Brewis R A L. (ed.) (1991), Classic Papers in Asthma. Volume 2:
Treatment. London: Science Press, 1–4. 
12 Solomon Solis-Cohen (b. 1857) was Professor of Clinical Medicine and Therapeutics, Philadelphia Polyclinic
and College for Graduates in Medicine from 1887 to 1902. See Solis-Cohen S. (1900) The use of adrenal
substances in the treatment of asthma. Journal of the American Medical Association 34: 1164. 
13 Bullowa J J M, Kaplan D M. (1903) On the hypodermic use of adrenaline chloride in the treatment of asthmatic
attacks. Medical News 83: 787–790. See Brewis R A L. (ed.) (1991), note 11, 106–109.
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in terms of the treatment of asthma. In terms of modern management and aerosol
drug delivery,14 it wasn’t until 1929 when Camps, a surgeon to the Teddington
Cottage Hospital, described giving his patients what appears to be nebulized or
atomized adrenaline. To quote him:
‘...the medicine was administered at bedtime for three to five minutes, at
seven litres of oxygen per minute, after a few nights the nocturnal attacks
were prevented and the asthma habit was broken. Cessation of treatment
was not followed by any return while the patient was living an ordinary life,
until some gross error of living or other accident, such as contagion of a
cold or family anxiety, brought back attacks which yielded again at once to
the treatment.’15
I think this brings us up to the current treatment and some of the drugs that we 
still use.
Godfrey: I would just add one point to that. A few months ago I was at a meeting in
Marburg, Germany, and came across an antique shop selling antique medical
equipment, and books, and one of the things was a nebulizer dating from 1910. It had
a little kettle that heated water and sent a jet of steam across a T-piece, which is exactly
like a jet nebulizer, and the medication went into a mouthpiece. It was thought to be
about 1910, but of course they had nothing to put in it. But there were jet nebulizers
at least 90 years ago. 
Chris, thank you very much for that introduction. We wondered at this time whether
Dr Frankland might like to tell us something, reminiscing a little bit about the history
of asthma in his youth, or before his youth, about childhood asthma and what he can
remember of its management.
Dr Bill Frankland:16 Thank you, Mr Chairman. My name is Bill Frankland and I
think, along with Archie Norman, I am probably the oldest person here. Oh, I am
sorry, and Chris Booth (we could have a contest). 
I thought I would describe what I was seeing 63 years ago and I would like briefly to
describe three patients. They were all connected to the extent that there’s something
that goes wrong with the definition of asthma. And I must remind you of course, this
14 For a recent review of aerosol delivery systems, see Taburet A M, Schmit B. (1994) Pharmacokinetic optimisation
of asthma treatment. Clinical Pharmacokinetics 26: 396–418.
15 Camps P W L. (1929) A note on the inhalation treatment of asthma. Guy’s Hospital Reports 79: 496–498, quote
on page 497. See Brewis R A L. (ed.) (1991), note 11, 115–117.
16 Dr Bill Frankland FRCP (b. 1912) began working in the Allergy Clinic at St Mary’s Hospital, London, in 1946.
He started the Daily Pollen Count in 1949 and gave it to the news media by 1951. In 1953 he published the first
double-blind controlled trial of an allergic disease, namely, seasonal hay fever. In 1956 he became Consultant at St
Mary’s Hospital, in charge of the Allergy Clinic. On retirement, he worked for 20 years at Guy’s Hospital, London,
as an Honorary Consulting Allergist. He has been Vice-President of the National Asthma Campaign and President
of the Anaphylaxis Campaign.
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17 Leonard Colebrook FRCOG FRCS FRS (1883–1967) joined Almroth Wright at St Mary’s Hospital in 1906,
becoming interested in puerperal fever in women following childbirth. In 1935 he successfully treated a woman
with puerperal fever with the newly discovered antibacterial drug Prontosil. He was responsible for the clinical
trials, under the MRC, that established the efficacy of sulphonamides (derivatives of Prontosil).
18 Charles McMoran Wilson (first Baron Moran of Manton from 1943) MC Kt FRCP (1882–1977) was
Consulting Physician, St Mary’s Hospital, London, and Dean of St Mary’s Hospital Medical School from 1920 to
1945, and President of the Royal College of Physicians from 1941 to 1950. See Lovell R. (1992) Churchill’s Doctor:
A biography of Lord Moran. London: Royal Society of Medicine Services. See also his autobiography, Moran C M
W. (1984) The Anatomy of Courage. London: Keynes Press for the British Medical Association. First published in
1945 by Constable and Company Ltd.
is the pre-antibiotic era, and although I had seen Leonard Colebrook17 treat puerperal
sepsis with Prontosil rubrum at Queen Charlotte’s Hospital. Sixty-three years ago we
didn’t have a sulphonamide to treat asthmatics. 
I was called from my room before 4 o’clock in the morning. My room, incidentally,
was the room where penicillin had been discovered in 1928. If I could just waste a little
more of your time by saying, of course, that the mould spore, Penicillium notatum,
which contaminated that plate had flown in from the allergy department beneath
Fleming’s laboratory. At that time the allergy department was looking into the possible
causes of mould spores causing asthma. Anyhow, I went down at 6 o’clock to see a
patient and this infant was 12 months old, and the mother said that her boy had been
wheezy and coughing nearly all his life; every cold caused severe wheezing. He had
developed a cold two days previously and she was going to bring it along to the
hospital (they all just came along to the hospital to the casualty department as it was
then called), but with her eight other children she was so busy she didn’t have time.
That particular morning the child had changed a lot, the coughing and wheezing had
stopped and he had changed colour and she was worried. And here was I at 6 o’clock
in the morning seeing my first case of what I thought was acute asthma. This story was
all lies, the child was quite cold; he had obviously been dead for some considerable
time. I remembered my previous teacher, Dr Wilson – you know him better as Lord
Moran,18 Churchill’s doctor – had said that history was so important, but no one had
ever suggested that the history you take might be a packet of lies. 
Now briefly, the next case I saw two months later, I was on duty at 2 o’clock in the
afternoon, and the nurse said would I please urgently see a boy who was having
difficulty in breathing. She thought that I might have to admit this child to the ward,
because it had acute asthma. In fact, this boy aged 12, didn’t have acute asthma. He
had had a sore throat the previous day and that morning speech was difficult, eating
was difficult, and now breathing was difficult. I gave one look at the throat and saw
a diphtheritic throat, I thought, and the reason I remember this particular case is that
I had never used force on any patient before or since, or ordered so much force to be
used. As soon as I said to the mother, ‘He will have to go to the Western Fever
Hospital, because he has got diphtheria, I think, and I have to take a swab before he
goes,’ the boy shut his lips very tightly and would not allow this to be taken. So I got
three hefty medical students, two of them in St Mary’s rugger team, two nurses and
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myself, and while I held his nose, we got a very good view of that throat. I took a
swab and said, ‘Let go’, as I was causing acute obstruction with the tongue depressor
and he went almost blue. The first cough that he took, very near my face, went all
over me. Now that is another story, the bilateral membranous conjunctivitis that I had
three days later, that’s something different. I apologized to the mother that we had to
use force, but I said that it was essential that I got a good view of that throat, and she
said, ‘Oh what a pity’. The reason he was so difficult, of course, was that his school
friend had been sent to the same fever hospital three days earlier with diphtheria. This
was a bit of the history that I hadn’t got. And she added, ‘And from his form two days
before, he had difficulty in breathing and was given an operation on his throat, and
he died on the table. That’s why my son didn’t want to go to this fever hospital.’
My third and final case – am I allowed a third case? I was asked to see a boy in the
ward because my boss then was Dr W D W Brooks19 of the Brompton, and I suppose
they thought I would know something about asthma. This boy, aged five, had his
eighth admission in about ten weeks to the children’s ward with acute asthma and I
had never seen so many notes as on this one boy, all from the social workers. His
mother was a prostitute, she wasn’t even a Paddington one, she had a place just off the
square in Mayfair – upmarket – and she was actually very pleasant. The father, on the
other hand, was an alcoholic, but generally in prison. The story was that the boy had
this intense fear of his father, he really was terrified of his father. I don’t know if anyone
here has ever seen a one-cause asthma due to emotional causes, but everyone agreed
that this was the cause. The reason I was asked to see this boy was that a new
houseman had noticed that during his first admission and the last two admissions, the
father was in prison (in fact he got a two-year sentence the last one), so he couldn’t be
the cause. I took a different history and the boy, of course, had a cat and he knew he
was cat-sensitive, it had caused trouble to his eyes, to his nose, and if the cat scratched
him, to his skin, and also caused him asthma. So I said, ‘Why didn’t you tell anyone,
you have been in here eight different times and you know the cause of your asthma
and you have never told anyone?’ He said, ‘No one has asked me whether I have a cat
at all, you are the first person.’ I said, ‘Why didn’t you tell them that you knew the
cause?’ He started crying and said, ‘Well my cat produced kittens on my bed two days
before I came into hospital, I know what you will advise, you will advise me to get rid
of the cat,’ and he cried and cried and cried. I think somehow that he had one-cause
asthma due to allergy. In retrospect, St Mary’s Hospital, where this was happening,
had an outpatient allergy clinic at the beginning of the century run by Dr John
Freeman, and after a few years he got in Dr Leonard Noon to help him with his work.
Dr Noon wrote the first paper on desensitization.20 The only difference between Noon
and his investigations and possibly ours, was that he did conjunctival tests and we did
19 Dr Donald Brooks CBE FRCP (1905–1993) was a physician specializing in chest diseases at St Mary’s Hospital,
London, from 1935 to 1970 and from 1938 on the staff of the Royal Brompton Hospital, London. See Lovell 
R R H. (1994) William Donald Wykeham Brooks. Munk’s Roll 9: 57–59.
20 Noon L. (1911) Prophylactic inoculation against hayfever. Lancet i: 1572–1573. Freeman J. (1911) Further
observations of the treatment of hay fever by hypodermic injections of pollen vaccine. Lancet ii: 814–817. 
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skin-prick tests on this boy to confirm that he was allergic to cats. We didn’t use a
histamine-positive control, because 60 years ago, of course, antihistamines hadn’t
come along. Those are three patients where the history was not quite what one
thought it might be. 
Godfrey: Thank you. My father was a medical student and later a doctor at St Mary’s
Hospital about that time, so the names are very familiar to me. Dr Norman, could we
encourage you to say a word or two about how asthma was treated as long ago as you
can remember.
Dr Archie Norman:21 Thank you very much, Simon. My memory of almost all the
things you want to hear about is extremely faulty and where it is not faulty, it tends
to be erroneous, so don’t trust too much. To cap Bill Frankland’s story, I just happen
to remember I recommended that a dog should be taken away from the house because
an asthmatic child appeared to be sensitive to the dog. The family came back to see
me a month later and said that they had had a burglary the next day. 
My impression when I was a student and a houseman is that asthma in childhood then
was very much what you might call an ‘orphan disease’. Nobody was that interested
in it. There was no adequate treatment and children didn’t ordinarily die from it, so
the principal physicians really tended to pay it little attention. What treatment there
was, as I can remember just after the war, was ephedrine and things of that sort.
Potassium and stramonium were very popular, for asthma and for whooping cough.
Antihistamines were tried extensively with, I think, no success, although we thought
there was some. But there was no really effective safe treatment until, I would have
thought, the 1950s or 1960s. 
Concerning steroids in the 1960s and the 1970s,22 I saw a number of children with
extremely severe asthma – stunted, ill, never at school. When treated with
prednisone,23 say 5–10 mg daily, they could return to what appeared to be a normal
life and normal schooling and this was a great result because they were no longer
thought to be dim and unfit for school. They were normal children for that time. But
of course after a year or so, it was becoming manifestly unsafe to continue with an
asthma-controllable dose of prednisone or steroids and one had to stop.
Godfrey: I think Dr Morrow Brown is going to talk a little bit about steroids later.
21 Dr Archie Norman MBE FRCP (b. 1912) was assistant Tuberculosis Officer to the Middlesex County Council
in 1939, before his War Service from 1940 to 1945. He was appointed Physician to the Great Ormond Street
Hospital in 1950, where he developed the Respiratory Unit, until his retirement in 1977. He was Chairman of the
Research Committee of the Cystic Fibrosis Trust from 1978 to 1984. 
22 For early use of corticosteroids see the Introduction to Brewis R A L. (ed.) (1991) Classic Papers in Asthma. 
Vol. 2: Treatment. London: Science Press. 
23 Prednisone, a systemic glucocorticoid taken orally, is used as an anti-inflammatory to treat acute asthma,
becoming active only after conversion in the liver to prednisolone. 
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Norman: What I would like to add is that we had a number of deaths, and my
impression was that the danger was in diminishing and stopping the dose. It was after
that, that the children became suddenly ill and there were occasional sudden deaths.
I think that’s really all you want to hear at the moment.
Godfrey: Thank you very much. I am sure you will join in later. I actually went to a
library and got out a couple of papers from Great Ormond Street about that time, a
little bit before your time actually. In the fifth volume of the Archives of Disease in
Childhood, 1930, there is a paper by Bray on childhood asthma.24 It is no less than 18
pages long, it has a 111 references, and not a single word, not one word, about
treatment. The only thing it does have is about prevention, prophylaxis, and it says
here, ‘Allergics shouldn’t marry each other’.
Norman: I think your friend Maimonides and others, later, did a great deal of harm by
saying that asthma was an emotional condition. Even in the 1930s, I have a little book,
The Nervous Child, by Hector Charles Cameron of Guy’s, saying just the same thing.
Godfrey: In 1928, also from Great Ormond Street, Pearson and Wyllie talk about the
treatment of asthma in Recent Advances in Disease of Children. They talk about
prevention, which is no different from Maimonides – hygiene, fresh air and not too
much sex or whatever, except that’s irrelevant, as it was paediatrics. They do actually
talk about treatment of acute attacks which include potassium iodide, stramonium,
and during an attack adrenaline. If this fails, morphia, one-twelfth of a grain for a
child of six years, hypodermically to be effective, or ephedrine hydrochloride, a
quarter to a half a grain by mouth, was recommended.25
The other interesting thing, from Great Ormond Street of that time, was a survey of
paediatrics outpatients, of whom only 1 per cent were asthmatic in the early 1930s. I
suspect it is probably a little higher than that these days. What was it like in your day,
Professor Warner?
Professor John Warner:26 I just wanted to say something about morphine, Simon. It’s
interesting that even into the 1960s and early 1970s, there were still physicians who
believed that a very small dose of morphine was an appropriate treatment for acute
asthma. When I was a registrar at the Queen Elizabeth Hospital in Hackney in 1973
there was still a consultant there who insisted that his patients should be given a small
dose of morphine when admitted with acute asthma. All the SHOs and registrars
would carefully steer him away from these patients because they were absolutely
24 Bray G W. (1930) The asthmatic child. Archives of Disease in Childhood 5: 237–258.
25 Pearson W J, Wyllie W G. (1928) Recent Advances in Diseases of Children. London: J & A Churchill, 336–337.
26 Professor John Warner FRCP FRCPCH FMedSci (b. 1945) has been Professor of Child Health in the University
of Southampton since 1990, having qualified at the University of Sheffield and worked at the Hospital for Sick
Children, Great Ormond Street, London, and the National Heart and Lung Institute, London (part of the
Imperial College of Science, Technology and Medicine’s new Biomedical Science Faculty from 1995). His main
interests are in the early-life origins of asthma and related allergic disorders.
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petrified of ever using morphine, and would use various forms of subterfuge to avoid
confrontation over the issue. Such comments as, ‘The patient was admitted just before
your take started’, or ‘Casualty had already given him some nebulized salbutamol. The
patient improved so much it was not necessary to administer morphine.’
Professor Tony Milner:27 Can I follow that? When I was a medical student, we used
to go down to Pembury, where there was a certain Dr Jacoby who knew how to treat
asthma: [Godfrey: That was him! The only paediatrician to do his own surgery for
pyloric obstruction.] He certainly gave good doses of morphine and it certainly
seemed to work. I have seen children admitted with really severe asthma, who were
given morphine. A look of satisfaction came on to their faces, they stopped wheezing
and they didn’t go blue!
Godfrey: Anybody else like to mention the advantages of morphine?
Professor Ross Mitchell:28 I am based in Dundee now, but in 1947 I was in Liverpool.
I wasn’t going to talk about morphine, but, taking up Professor Godfrey’s second point
about the frequency of asthma in hospital, I would say that in Liverpool in 1947 we
thought of Great Ormond Street and St Mary’s Paddington as rather rarified
atmospheres. In the rough and tumble of provincial hospitals like the Royal Liverpool
Children’s Hospital, the wards were full of children with tuberculosis, leukaemia,
rheumatic carditis, empyema and bronchopneumonia, and we considered asthma as a
comparatively minor condition to be treated for the most part in general practice and
seldom admitted to hospital. If children came in status asthmaticus, we gave them
adrenaline in the outpatient department. By contrast with the children who were ill
and dying in the wards, we didn’t rate asthma so highly then and it was that much less
common. Even in 1953 when I was working in the Allergy Section of the Mayo
Clinic, allergy and asthma were looked upon rather disdainfully by other specialities.
Mrs Eleanor Hickie:29 I developed asthma at the age of four in 1943. Two things
happened then: my father was shot down, missing and presumed dead, and my
mother started smoking all on the same day. And although my father returned at the
end of the war, my mother didn’t stop smoking. I remember from four until 17 I spent
my life in a frenzy of atropine and adrenaline and then being sedated until I could
barely breathe, so I can’t actually say much for the idea that sedation did help at all.
On the last occasion I was actually given two tablets of Soneryl and I managed to
27 Professor Anthony Milner FRCP (b. 1938) was Professor of Neonatology at the Guy’s, King’s and St Thomas’
Hospital Medical School of King’s College, London, from 1990 to 2000, later Emeritus. He had been Professor
of Paediatric Respiratory Medicine at the City and Queen’s Medical Centre, Nottingham, from 1982 to 1990.
28 Professor Ross Mitchell FRCPEd FRCPCH (b. 1920) trained in paediatrics in Liverpool, Edinburgh, and
London, and held a Rockefeller Research Fellowship at the Mayo Clinic, Rochester, Minnesota, USA. He was
Professor of Child Health in the University of Aberdeen from 1963 to 1972 and in the University of Dundee from
1973 until his retirement in 1985, later Emeritus.
29 Mrs Eleanor Hickie (b. 1939) has been a staff nurse at the Queen’s Medical Centre, Nottingham, from 1992
to 2001.
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secrete them in the back of my mouth and didn’t swallow them. In the morning the
consultant almost decapitated the registrar and I have never been sedated since. My
asthma has almost improved since I stopped eating nuts four years ago. I don’t use a
nebulizer or inhaler at all.
Professor Tim Clark:30 If we are talking of sedation and asthma, just briefly I can
remember Mac Cochrane and I carried out a survey of deaths from asthma in
London31 in what was then known as the GLC [Greater London Council, 1964 to
1986], this was [Ken] Livingstone’s era. I can’t remember the percentage, but we
found a considerable proportion of those who died in the GLC area had taken
sedation in one form or another. We then decided we should try to do what was a very
rudimentary case control study and look at other patients admitted who hadn’t died
and found that an equally large proportion had also had the sedation. We included
that in the paper published in Thorax but that section was rejected by the editors as
being without interest. So it never appeared. 
Professor Jack Howell:32 Dr Pearson’s name has been mentioned and I associate his
name with the recognition of nocturnal dyspnoea and there may not be another
opportunity to bring this in,33 but I think it is such an important observation, such a
crucially important symptom in asthma, that it’s worth mentioning, and if I am
correct, I think in this country at least, he takes credit for it. [From the floor: 
He shouldn’t.] 
Godfrey: I am into this in a big way at the moment because this is what my sabbatical
is about. Sir John Floyer wrote that the fit begins about two in the morning, induced by
the heat of the bed or words to that effect. He very clearly described nocturnal asthma.
30 Professor Tim Clark FRCP (b. 1935) has been Professor of Pulmonary Medicine at Imperial College, London,
from 1990 and its Pro-Rector from 1995 to 1997 as well as serving as Provost of Imperial College at Wye from
2000. He qualified in 1961 and was Consultant Physician at Guy’s Hospital, London, from 1968 to 1990 and at
the Royal Brompton Hospitals, London, from 1970 to 1998. He was Dean of the United Medical and Dental
Schools of Guy’s and St Thomas’ Hospital (Guy’s, King’s and St Thomas’ School of Medicine, Dentistry and
Biosciences since 1998), London, before becoming Dean of the National Heart and Lung Institute (merged with
Imperial College of Science, Technology and Medicine as part of its School of Medicine in 1995), London. He
was President of the British Thoracic Society from 1990 to 1991 and Vice-Chairman of the National Asthma
Campaign from 1992 to 2000.
31 Cochrane G M, Clark T J H. (1975) A survey of asthma mortality in patients between ages 35–64 in the Greater
London Hospitals in 1971. Thorax 30: 300–305.
32 Professor J B L (Jack) Howell CBE FRCP (b. 1926) qualified at the Middlesex Hospital, London, in 1950 and
held an MRC Fellowship at Johns Hopkins Hospital, Baltimore, Maryland, from 1957 to 1958. He was Senior
Lecturer and Consultant Physician at the Manchester Royal Infirmary from 1960 to 1969 and Foundation
Professor of Medicine at the University of Southampton from 1969 until his retirement in 1991, later Emeritus,
and Dean of the Faculty of Medicine from 1978 to 1983. He was President of the British Thoracic Society from
1988 to 1989 and of the British Medical Association from 1989 to 1990 and Chairman of the Southampton
Health Authority from 1983 to 1998.
33 Professor Jack Howell wrote: ‘I must accept that I was mistaken because I have searched the Quarterly Journal of
Medicine throughout the 1930s–1950s and the paper I thought I recalled was not there. So I can’t even confirm that
I was confusing nocturnal dyspnoea with a study of exercise-induced asthma, which is my alternative thought. In any
event, I precipitated half-a-dozen subsequent entries based on this error.’ Letter to Mrs Lois Reynolds, 1 April 2001.
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Howell: I believe that this paper which I think was in the Quarterly Journal of
Medicine was really on a different plane. I think it is worth recording it, if true. I
would like to go back and check it.
Godfrey: Was that before Margaret Turner-Warwick and the Brompton people with
the morning dipping?34
Clark: Henry Hyde Salter recognized the diurnal variation. I agree Floyer did before
him, but I doubt if Floyer was the first.
Godfrey: We started discussing asthma deaths, deaths from asthma and as everybody
here is aware the epidemic of asthma deaths affected primarily children, young people,
and we thought this would be an important topic to consider and I have asked Chris
O’Callaghan to lead off and then we will all add our little bits and I think he is going
to read some information he received from Charlie Thiel.
O’Callaghan: I would like to relate to you some written information we received from
Charlie Theale, who was one of the chemists at Riker 3M in 1956 when the first
metered dose inhaler was developed. The drug used was isoprenaline, developed in the
1940s and released in 1951 from Boehringer-Ingleheim. I looked through the various
journals to find information on asthma at this time, particularly the British Medical
Journal, and found very few articles during the 1950s and the early 1960s on asthma.
The great increase in articles on asthma appeared to go hand in hand with the
development of the first metered dose inhaler. In fact the adverts for Guinness
outweighed those for asthma by a factor of ten in 1962, but that rapidly changed. 
This is from Charlie Thiel.35 Early in the spring of 1955 one of his bosses, Dr Maison,
who I understand also invented the G-suit for fighter pilots, had a 13-year-old
daughter with asthma, whose name was Susie. She used to frequently complain that
the glass squeeze-bulb nebulizer she used for her isoprenaline kept breaking. She asked
her father, ‘Why can’t they put my asthma medicine in a spray can like they do hair
sprays?’ Dr Maison was President of Riker Laboratories and the next day he
approached Mr Irving Porush, head chemist in their three-person pharmaceutical
development laboratory, to see if he could make a pressurized inhaler of a
bronchodilator. Literally down the corridor was a cosmetics laboratory where he went
for advice from colleagues who formulated hairsprays. They provided Porush with
some background materials, equipment and supplies. In April 1955 he ordered some
propellants from DuPont, borrowed an old ice-cream freezer from the Rexall drug store
downstairs, bought an empty case of cola bottles and a bottle capper. Thus equipped
he set out to formulate pressurized aerosols of epinephrine and isoproterenol. Before
34 Al-Damluji S, Thompson P J, Citron K M, Turner-Warwick M. (1983) Effect of naloxone on circadian rhythms
in lung function. Thorax 38: 914–918
35 Thiel C G. (1996) From Susie’s questions to CFC free: An inventor’s perspective on 40 years of MDI
development and regulation. Respiratory Drug Delivery 5: 115–123, material above from 115–117.
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36 Committee on Safety of Drugs. (1967) Aerosols in asthma: Vaccines. Adverse Reactions Series No. 5. London:
HMSO. 
37 Dr James Spowart McCracken MBE FRCGP (b. 1930) is now a retired principal and lecturer in general practice
at the University of Nottingham. He edited two volumes of Sport, Exercise and Medicine in 1995 and was President
of the Nottingham Medico-Chirurgical Society from 2000 to 2001.
38 McCracken J. (1997) A memorable patient: Death in the Scottish Highlands. British Medical Journal 315: 408.
coming to Riker Irving [Porush] had been a chemist for the Coca-ColaTM bottling plant.
He knew that the cola bottles could hold about 1300 pounds per square inch internal
pressure and they would be ideal for experimenting with. Irvine’s formulation consisted
of a drug with ascorbic acid, as an antioxidant, dissolved in alcohol and diluted to weight
with propellants. Just prior to this, in about 1954, Phillip Meshberg had patented a
metering valve that he envisaged would be useful for perfumes. They negotiated the use
of his patent and together with the Wheaton Glass Company, who made little glass
phials with a vinyl plastic around them, they assembled the first pressurized metered
dose inhaler. It consisted of a Meshberg valve, a Wheaton Glass perfume bottle, and the
drug inside. The actual plastic coating had a hole in the bottom and they thought that
if it got overheated and exploded, the contents would come out of the little hole in the
bottom and the glass wouldn’t fragment into the patient.
Simple animal exposure studies were done as safety checks. The first clinical trial was
carried out by Dr Karr at the Veterans Administration Hospital in Long Beach,
California, in 1955. The treatment seemed to be effective and on 9 March 1956 the
MedihalerIso and the MedihalerEpi, were launched. Around this time they patented
various things to put in metered dose inhalers, including nicotine, which never got
launched. They trialed insulin, and although it made animals hypoglycaemic, it was
considered far too variable to launch on the public. They also formulated ergotamine
[Medihaler Ergotamine, 3M], which was launched and I believe it either is still
available or was available until recently for the treatment of migraine. The actual
solution was of alcohol, and the metered dose inhaler had a long pipe in front of it to
reduce the unpleasant effect of 50 per cent ethanol hitting the back of the throat. 
A couple of years later Charlie Thiel reformulated these drugs as suspensions. This
nearly cost Riker their business, as patients had associated the foul taste of alcohol
with feeling better. The suspension without a foul taste had to prove itself again. In
terms of popularity from that stage onwards, the metered dose inhalers have grown
phenomenally. Over 500 million are sold per year. Unfortunately during the 1960s it
was noticed that there was an epidemic of asthma deaths that seemed to be strongly
linked to the development and the use of metered dose inhaler.36
Godfrey: Well I think maybe we could ask Dr McCracken at this stage to say
something about his personal experience of asthma deaths in young people and then
we will discuss more generally the whole question of the epidemic of asthma deaths.
Dr James McCracken:37 My contribution really originates from a memorable patient
article published in the British Medical Journal of 1997.38 It’s one thing to read these
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anecdotes, but another to listen to them being read. One tends to feel that it’s like
watching paint dry, so what I would like to do is to briefly describe it and use my
contribution as a means of jogging your memories about the level of our awareness of
asthma during the 1950s. I understand that you all have a copy of the article in your
folders. It was called ‘Death in the Scottish Highlands’. 
I graduated in the late 1950s in Aberdeen and was at that time working as a locum,
my first locum. At around 2 o’clock in the morning, I was called to a patient’s bedside
from my hotel where I was staying. All I knew was that the patient was having an
asthma attack, a 16-year-old, who was well known to us in the town as an attractive
girl who used to serve the teas at the local cricket club. I knew all about asthma, my
goodness I had learned it all up by then. So, driving along at 2 o’clock in the morning,
I remember thinking that the village was on the other side of the world from Buckie,
ten miles away in my Morris Eight. I was a bit peeved and I kept thinking to myself,
‘Has she taken her tablets containing phenobarbitone – Franol tablets?’39 (Everybody
who had the slightest suggestion of bronchospasm was on Franol tablets for the next
20 years.) ‘Was I expected to give her subcutaneous adrenaline,’ because to do so
would medicalize the problem and succeeding emergencies would have to be dealt
with in the same way? ‘No, I didn’t feel inclined to do that’. ‘Was her mother being
over-protective?’ After all we had been taught, ‘Get rid of the mother and you cure the
child’s asthma.’ ‘Couldn’t she have waited until the next morning?’ 
I eventually arrived at the village, but how to find the house? By God, it wasn’t difficult.
There was a loud wailing, banshee-like, spine-chilling lament coming from one of the
cottages and when I went in, the girl’s aunt who was looking after her, threw herself at
me, battering me on the chest to help, and the child was as dead as a post on the floor, a
16-year-old. Of course, I gave the subcutaneous adrenaline that I had intended not to
give. I knew full well she was dead by then. It was long before the days of mouth-to-
mouth resuscitation. End of story. I went home a chastened man. I found that I knew less
about asthma than I thought I knew. The village mourned and the practice went on with
its ministry. Just one small corollary to that. The editor of the British Medical Journal
asked me if I could possibly arrange to have confirmation of any relatives’ agreement to
this being published. Now, this was 40-odd years later and I didn’t think that it had been
the girl’s mother, but I contacted the senior partner whom I still knew. We regularly
exchange Christmas cards and although he’d retired by then, he well remembered the
case. No way had the case been forgotten up there. He put me in touch with the senior
nursing sister in the practice who was a 56-year-old, and yes, you’ve worked it out, she
well remembered the young girl. She had been in her class at school. She remembered the
house. She remembered the lot. It wasn’t history up there, I can assure you.
That’s the background to the story, but as I say I would like it to act as a sort of entrée
to what was happening in asthma awareness at that time. I would like you to look back
39 Franol is currently a proprietary combination of ephedrine hydrochloride and theophylline manufactured by
Sanofi Winthrop. In the 1950s it also contained phenobarbitone.
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and think – the Clean Air Act only came in, in 1958. The profession, far less the
public, was certainly not aware of any hazards from cigarette smoking. Life was lived
at a different pace. I still have a hand-written letter, addressed in the 1950s to a GP
from a consultant paediatrician in Nottingham (Professor Morrow Brown and
Professor Tony Milner will remember Dr Pat Page), where the last sentence reads,
‘Please excuse the handwriting, but the hospital secretary is on holiday at present’.
Life, as I said, was lived at a different pace.
I wonder if anybody who has graduated since 1960 remembers Tucker’s Cure? Tucker’s
Cure was actually used very effectively to alleviate bronchospasm. It was cocaine and
atropine given in a nasal atomizer. The term ‘snorting’ wasn’t in use then! In the
treatment of acute episodes of bronchospasm at that time, at least in the adult, your
first consideration was to identify between bronchial and cardiac asthma. In the first,
you really were dealing with the later effects of chronic bronchitis and emphysema, so
common in those days. With the other, the patient was drowning of acute congestive
cardiac failure. After all, digoxin had only just started to replace Digitalis folia. The
patient requiring diuretics could only get treatment by intramuscular injection in the
morning given by the district nurse. And hypertension was ‘treated’ only by
barbiturates. Congestive cardiac failure was common. Good old aminophylline40 you
will remember, was given in a long large slow intravenous dose, 500mg in 20ml, and
worked wonders. If cardiac asthma was suspected we used morphine or diamorphine
added to the aminophylline. 
I say in my article that my knowledge of asthma I had in those days had been gleaned
from my tutor and mentor in general practice, a wonderful old man. As an
undergraduate I had spent a month shadowing him. He was never without his
atomizer – a large rubber bulb with a glass reservoir – containing, I think, adrenaline
and ephedrine, but it might have been isoprenaline. [From the floor: Rybar was it?]
Every house we went into he would flop down in the nearest, most comfortable
armchair, puffing away at his atomizer. He would introduce me to the patient, ‘I have
brought a young specialist with me’ and I was a specialist in whatever the problem
happened to be. If it was the left knee I was a specialist not only in knees, but in the
left knee. He subsequently died in status asthmaticus in the mid-1960s, in the
middle of the dress circle, in the middle of an evening performance at the local
theatre, still clutching his atomizer. I say he was a wonderful old boy, although in
retrospect when he died he was probably a good ten years younger than I am today.
They still say those were the good old days. 
Godfrey: That’s an excellent introduction and I am going to ask Professor Michael
Silverman to read a piece that we have received from Professor Inman relating
obviously to the asthma epidemics of the 1960s. He unfortunately was unable to be
here because of his illness, but he very kindly wrote in and we have asked Michael to
present the material.
40 See note 131.
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Professor Michael Silverman:41 I am the voice of Bill Inman.42 This is in return for a
free lunch, I think. And he writes: 
‘As my lack of mobility prevents me from attending this meeting in person,
I have been asked to record a few words by way of introduction to what in a
recent book I have called ‘The Silent Epidemic’.43 The epidemic was silent in
its approach. It was massively damaging to the asthmatics of the mid-1960s
who were using pressurized aerosol bronchodilators. The epidemic passed
away with practically no publicity, in striking contrast with our experience
with oral contraceptives, which was occupying us very much at that time.
The problem was first identified by my former chief at the old
Addenbrooke’s Hospital in Cambridge, Dr Martin Greenberg, who wrote to
the Committee on Safety of Drugs to say that he was concerned that patients
using the new isoprenaline aerosols might be dying suddenly. Rather than
rush into print, he had reported his concern to the Committee, but I warned
him that the Committee would not act without further evidence and I
advised him to write to the Lancet. In children in the 5–14-year age group
for example there had been an increase in mortality rate of 330 per cent. In
June 1967 the Committee on Safety of Drugs issued a low-key warning,
advising parents to contact their doctors if their child had failed to achieve
the normal response to its inhaler. Because of the one to two-year delay in
publication of the UK vital statistics, Dr Adelstein,44 the Chief Medical
Statistician of the Registrar General’s office and myself were only able to
publish a paper which we called the ‘Rise and Fall of Asthma Mortality’ in
1969.45 We reported that there had been a steady rise in asthma mortality
running parallel to the increase in the sales of isoprenaline inhalers. It peaked
in mid-1965 at the time of Dr Greenberg’s first publication46 and then fell
gradually during the next three to four years. After the peak I noticed in the
41 Professor Michael Silverman (b. 1943) has been Professor of Child Health at the University of Leicester since
1995. He was at the Royal Postgraduate Medical School, Hammersmith Hospital, London, as Senior Lecturer in
Paediatrics from 1977 to 1992 and Professor of Paediatric Respiratory Medicine from 1992 to 1995.
42 Professor Bill Inman (b. 1929) qualified at Cambridge, acted as medical adviser to Imperial Chemical Industries
from 1960 to 1964, joined the Ministry of Health’s Committee on Safety of Drugs in 1964 as Senior Medical
Officer, later Principal Medical Officer, to develop its voluntary reporting system, and was Medical Assessor of
Adverse Reactions at the Ministry of Health until 1980.
43 Inman W H W. (1999) Don’t Tell the Patient: Behind the drug safety net. Los Angeles: Highland Park Productions.
Chapter 3, The Silent Epidemic, 61–79. 
44 Abe Adelstein FRCP (1916–1992) was Chief Medical Statistican for England and Wales from 1975 to 1981 and
Visiting Professor at the London School of Hygiene and Tropical Medicine from 1981 to 1984. He arrived in
England in 1961 from South Africa, having been director of research and medical statistics of the South African
Railways. See Marmot M. (1992) Obituary: A M Adelstein. Lancet 340: 1463. Professor Jack Howell wrote: ‘He
was also statistical adviser to Howell and Altounyan in their first clinical study of cromoglycate in 1965.’ Letter to
Mrs Lois Reynolds, 6 July 2001. See note 87.
45 Inman W H W, Adelstein A M. (1969) Rise and fall of asthma mortality in England and Wales in relation to
use of pressurized aerosols. Lancet ii: 279–285. idem Asthma mortality and pressurized aerosols. ibid. ii: 693.
46 Greenberg M J. (1965) Letters to the Editor: Isoprenaline in myocardial failure. Lancet ii: 442–443.
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Hospital In-Patient Enquiry (HIPE) estimates of discharges and deaths that
although the deaths were diminishing the hospital admissions and the
discharges continued to rise. This suggested that we were dealing not so
much with drug toxicity, but with over-confidence in a normally effective
form of treatment. When children became tolerant to the isoprenaline so
that it lost its effect, the danger was recognized too late and admission to
hospital was delayed. 
For several years I was a member of the Medical Research Council’s Asthma
Death Committee47 and I remember at one of our meetings suggesting that
we should look at the toxicity of the CFCs, the fluorocarbon propellants
used in the pressurized aerosols. I could see that Colin Dollery48 was
fidgeting in his chair and Sir Cyril Clarke, the Chairman, had hardly got to
the end of ‘Any Other Business’ when Colin grabbed his coat and briefcase,
and rushed out of the room. Two weeks later he had an article in the Lancet.49
The story was confirmed by Charles George who told me years later that
when Colin got back to his laboratory at the Hammersmith, he was pressed
into service as a volunteer. There was apparently no significant effect of
CFCs and many other hypotheses proposed at these MRC meetings failed to
explain this extraordinary epidemic. To conclude, I believe that both doctors
and patients had been lulled into a false sense of security by a new treatment
that was normally very effective, but that occasionally, once the patient
became tolerant to it, led to a delay in resuscitation. The increase in
mortality was relatively greatest in young patients, but all ages were affected,
except children under five, who were too young to use the aerosols. The
figures suggested that more than 3000 people died from asthma during the
epidemic, in excess of the expected or baseline mortality of perhaps one-third
this number and I have always been concerned that there could be another
47 ‘The Council’s Committee on Deaths from Asthma (Chairman: Sir Charles Stuart-Harris), which was set up in
February 1968 to keep under review the problem of deaths from asthma and to advise the Council on further steps
which might become necessary in the light of accumulating evidence, reported in June 1971. The Committee
recommended that doctors should be alerted to the risk of death in patients in unrelieved status asthmaticus, and
that the potential dangers of the excessive use of pressurized aerosols should be the subject of reminders to doctors
and warnings to patients. The Committee is to remain in existence for a further period to hold a watching brief
on deaths from asthma – particularly in young people – and to monitor the effects of changes in therapy; it hopes
to stimulate detailed clinical studies of patients in status asthmaticus and further work on the mechanism of
resistance to bronchodilator drugs.’ House of Commons. (1972) Medical Research Council Annual Report, April
1971– March 1972. HoC 326. London: HMSO, 31.
48 Professor Sir Colin Dollery Kt FRCP FMedSci (b. 1931) has been a senior consultant in Research and
Development at Smithkline Beecham plc since 1996. He was Consultant Physician at the Royal Postgraduate
Medical School, Hammersmith Hospital, London, from 1962 to 1996 and Lecturer in Medicine from 1962 to
1965, Professor of Clinical Pharmacology from 1965 to 1987, Professor of Medicine from 1987 to 1991 and Dean
of the Royal Postgraduate Medical School from 1991 to 1994 and Pro-Vice-Chancellor for Medicine and
Dentistry at the University of London from 1992 to 1996. He was a member of the Committee on Safety of
Medicines from 1966 to 1975.
49 Dollery C T, Davies D S, Draffan G H, Williams F M, Conolly M E. (1970) Blood concentrations in man of
fluorinated hydrocarbons after inhalation of pressurized aerosols. Lancet ii: 1164–1166.
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50 See note 43. See also, for example, www.societyguardian.co.uk/news/story/0,7838,438227,00.html or
www.open.gov.uk/mca/aboutagency/regframework/mc/mcsm900.pdf (visited 7 June 2001).
51 Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, Ball M, Beasley R. (1989) Prescribed fenoterol and
death from asthma in New Zealand, 1981–1983: a case-control study. Lancet i: 917–922. Suissa S, Ernst P, Boivin
J F, Horwitz R, Habbick B, Cockroft D, Blais L, McNutt M, Buist A S, Spitzer W O. (1994) A cohort analysis of
excess mortality in asthma and the use of inhaled beta-agonists. American Journal of Respiratory and Critical Care
Medicine 149: 604–610.
52 Dollery C T, Williams F M, Draffan G H, Wise G, Sahyoun H, Patterson J W, Walker S R. (1973) Arterial
blood levels of fluorocarbons in asthmatic patients following use of pressurized aerosols. Clinical Pharmacology and
Therapeutics 14: 59–66.
‘silent epidemic’. I remember the aggressive way which salmeterol was
promoted more recently, with the help of so-called post-marketing
surveillance studies, in which doctors were paid to include large numbers of
asthmatics, the majority of whom were probably being well controlled with
their current antiasthma therapy. I cannot resist the temptation to plug my
book, in which I recall the asthma epidemic and several other accidents with
drugs. It’s called Don’t Tell the Patient 50 and you can find out more about it
on the Internet.’ 
Thank you very much.
Godfrey: Would anybody like to comment on the epidemic? I would like to make just
one small comment and that is that those who don’t learn from history are doomed
to repeat it. Of course we have seen the epidemics, or apparent epidemics, of asthma
deaths with the fenoterol and probably other bronchodilators that occurred 20 or 25
years later in a similar fashion and disappeared and have generated the same argument
as to whether it really is or isn’t the drug or what’s the problem? So there was the 1960s
epidemic and, at least in New Zealand, although I believe in Canada too, the 1980s
to 1990s epidemic.51
O’Callaghan: I wasn’t around at that stage, but just reading through a variety of
literature on the asthma deaths, I think the propellants in the inhalers and the drugs
coming out of them were implicated. The background for that is the various work that
was done on animals – they used to get animals to inhale the propellants, the
fluorocarbons, and then exercise them in a laboratory. Provided they had inhaled
enough propellants, they would drop dead of a ventricular tachycardia. Similarly, if
they gave them propellants and then injected them with adrenaline, instead of
exercising them, they again got ventricular tachycardia and died.
Godfrey: You mean Colin Dollery got it wrong?
O’Callaghan: Well, I am not sure. In the anecdotal reports children were reported to
be seen clutching their empty metered dose inhalers. They would frequently go
through 200 shots in three or four days. So in some cases at least, they were using
them in excess. Dollery’s work52 suggested that the myocardium didn’t get the levels of
propellant that would sensitize it to these effects. In fact it got a tenth of that.
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However, if you got somebody to inhale the aerosol, as one of his volunteers did, on
every breath for 30 seconds at the rate of 12 breaths per minute, the actual amount in
the myocardium well exceeded the amount that would sensitize a dog’s heart to
injected adrenaline. Although people say that it’s very safe, in fact the work that he did
suggests that it may not be safe in excess. In the animal studies they found that one or
two of the dogs were highly sensitive and would die following exposure to very small
concentrations. So I think the jury is still out on what exactly caused the deaths. 
Professor Stephen Holgate:53 Around that time when the theory was being advanced,
there was another name that ought to be mentioned – Dr Szentivanyi. He advanced
a theory, based on an experimental animal model, that sensitization to allergens could
lead to downregulation of adrenoceptor function. At that time there was an intense
debate as to whether or not the fundamental cause of asthma was a decrease in
adrenoceptor function and that the reason why these patients needed to use so much
bronchodilator drug was because they had an impaired intrinsic response to it
(adrenergic resistance). However, by taking an excess of bronchodilator to achieve a
therapeutic effect, they were enhancing the cardiac side-effect of the propellants. It is
interesting to note that this theory has never really gone away, despite the fact that it
was based purely on an animal model. It remains in the literature to this day as to
whether or not there is a fundamental abnormality of the adrenoceptor system that’s
behind some of the pathophysiology of asthma. It’s fascinating to think that those
observations, which I think date back to the late 1950s when Szentivanyi first did his
experiments, have not really ever been disproven.54
Warner: It’s interesting if you look through historical publications on asthma, that in
the twelfth century Moses Maimonides’s book, Treatise on Asthma, where asthma
deaths were recognized to occur. He wrote that if, ‘the rules of management go
unheeded, asthma may well end in death’.55 Yet Osler56 at the beginning of the
twentieth century is supposed to have said that he had never seen an asthmatic die, he
talked about ‘asthmatics panting on into old age’. At least he recognized it was a
chronic condition that was life-long, even if he didn’t recognize deaths. Did he truly
miss all asthma deaths and ignore them or was it that there have been cycles increasing
and decreasing risk of asthma deaths? Even in the 1950s asthma was not viewed as a
53 Professor Stephen Holgate FRCP FIBiol FRCPath FMedSci (b. 1947) has been MRC Clinical Professor of
Immunopharmacology at the School of Medicine in Southampton since 1987. He has been Director of the
Respiratory Cell and Molecular Biology Division within the Medical School at the University of Southampton
from 1968. He chaired the Department of Health’s expert group, the Committee on the Medical Aspects of Air
Pollutants, from 1992 to 2001. See Holgate S T. (1994) Antihistamines in the treatment of asthma. Clinical
Review of Allergy 12: 65–78.
54 Szentivanyi A. (1968) The β-adrenergic theory of the atopic abnormality in bronchial asthma. Journal of Allergy
42: 203–231.
55 See note 4.
56 Sir William Osler FRCP FRS (1849–1919) was Regius Professor of Medicine at the University of Oxford from
1904 until his death. See Osler W. (1892) The Principles and Practice of Medicine: Designed for the use of practitioners
and students of medicine. Edinburgh: Young J Pentland.
Childhood Asthma and Beyond
21
potentially fatal disease. I have an extract from a ship’s captain’s medical guide from
1952, talking about asthma: 
‘...attacks are considered to be due to peculiar sensitiveness of the patient to
nervous upset or to certain irritants like dust. Although often very
distressing, asthma is not a dangerous disease.’57
Sir David Jack:58 I’m formerly of Allen & Hanburys and Glaxo. We also did studies in
dogs and found that normal animals tolerated multiple inhalations of isoprenaline
delivered from pressurized inhalers. The propellants were therefore unlikely to be a
primary cause of the unexpected deaths associated with excessive use of inhalers.
However, when repeated inhalations of the isoprenaline aerosols were given to hypoxic
dogs some of them died with cardiac arrest in diastole.59
I believe that hypoxia was also a critical factor in the deaths of patients who used their
isoprenaline inhalers increasingly despite a waning response to the drug and steadily
worsening asthma. Unfortunately for the victims, these were consequences of progressive
physical occlusion of the airways and not of pharmacological tolerance to isoprenaline.
Further inhalations of the drug were lethal because they increased the oxygen requirement
of an already hypoxic heart and, at the same time, may have reduced its oxygen supply
by lowering the blood pressure and, therefore, coronary flow. The outcome was death,
probably following cardiac arrest in diastole. All of this emphasizes the need for
appropriate steroid treatment to contain inflammation in the airways of asthmatics.
Dr Ian Gregg:60 Referring to Professor Warner’s remarks about Sir William Osler’s
dictum that asthma never caused deaths, I believe that in the context of Osler’s
57 Ministry of Transport and Civil Aviation. (1952) The Ship’s Captain’s Medical Guide. London: HMSO. Quote
on page 167.
58 Sir David Jack Kt CBE FRSE FRS (b. 1924), a pharmacologist, has been associated with new medicines for
asthma (Queen’s Awards for salbutamol, 1973; inhaled beclomethasone dipropionate, 1975), hypertension, peptic
ulcer (Queen’s Award for ranitidine, 1985), nausea and migraine. He was a scientist in the Glaxo Laboratories from
1951 to 1953; Head of Product Development at Smith Kline and French from 1953 to 1961; Research Director
of Allen & Hanburys, a constituent part of Glaxo, from 1961 to 1973 and Managing Director of Allen &
Hanburys from 1973 to 1978; and Research and Development Director of Glaxo Holdings from 1978 to 1987.
59 Sir David Jack wrote: ‘A similar sensitivity to β-agonists was found by Shanks and his colleagues in Belfast in
anaesthetized dogs made hypoxic by inhaling nitrogen-enriched air.’ Comment on draft transcript, 15 January
2001. Shanks R G. (1966) The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline
and noradrenaline in the anaesthetized dog. British Journal of Pharmacology 26: 322–333. Black J W, Duncan 
W A, Shanks R G. (1965) Comparison of some properties of pronethalol and propranolol. British Journal of
Pharmacology 25: 577–591.
60 Dr Ian Gregg FRCP FRCGP (b. 1925) was in general practice in London from 1958 until his retirement in 1987.
Much of his research was carried out in association with the then Cardio-Thoracic Institute (later Royal Brompton
Hospital, London), where he was Director of an extramural Department of Clinical Epidemiology. His special interests
have been the assessment of bronchial airflow by PEF (peak expiratory flow) in collaboration with Dr Martin Wright
(1912–2001), the inventor of peakflow meters, the roles of bacterial and virus infection of the bronchi and the
epidemiology of asthma worldwide. See Anonymous. (2001) Martin Wright. The Times, 23 March, 25; Wright C M.
(2001) Basil Martin Wright. British Medical Journal 322: 1308. For details of Wright’s work at the MRC, see Reynolds
L A, Ness A, Tansey E M. (eds) The MRC Epidemiology Unit (South Wales). Wellcome Witnesses to Twentieth Century
Medicine. vol. 13. London: Wellcome Trust Centre for the History of Medicine at UCL, in press. 
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experience of asthma in hospital practice, his observation was correct.61 At the time he
wrote those words, there seems very little evidence that deaths from asthma in
hospitals were at all common. I have studied the records of three London hospitals
from 1880 to 1930 and found that before the First World War almost no children and
very few adults were admitted with asthma, and there were no deaths. From 1919
onwards, admissions of children increased, but to a much greater extent in adults, in
whom there were 11 deaths.62
But going back to the whole question about the cause of death in the so-called
epidemic of asthma deaths that occurred in the 1960s, there appeared at the time to
be a strong temporal association between deaths and the use of pressurized metered
aerosols containing isoprenaline, particularly the stronger of the two preparations,
iso-forte. It has been my understanding that when these deaths were reviewed some
years later, only about a third of them were linked with the taking of isoprenaline.63
I think that comes back to really a more fundamental question still, and that is this:
when one considers the relative frequency of asthmatic attacks and fatality, why, in
the absence of treatment or what we would now regard as good modern treatment,
why were deaths so uncommon? So, why is it that once an attack has begun, it does
not invariably progress to total obstruction of airflow and death? Is there some
mechanism that can terminate the process but occasionally fails to do so and in that
case, death follows? 
Finally when Simon [Godfrey] referred to the treatment of acute asthma in children
at Great Ormond Street in the 1930s with injected adrenaline or ephedrine by
mouth,64 I was reminded of a discussion we once had many years ago about the relative
merits of selective adrenoceptor agonists and ephedrine. My argument was that
whereas they may have been selective agonists and had fewer cardiac effects, ephedrine
is an analogue of adrenaline and therefore has ‘pan-adrenergic’ properties.65 Would
someone like to comment on these two issues?
Dr Alistair Brewis:66 I was only just going to add a comment to balance the focus that
we had earlier on the toxicity or possible toxicity of the components of the
61 Dr Ian Gregg wrote: ‘In the first edition of his Principles and Practice of Medicine, 1892, Osler wrote, “Death during
the attack is unknown”.’ Letter to Mrs Lois Reynolds, 30 March 2001.
62 Dr Gregg has been undertaking a study of deaths from asthma from 1700 to the present and the prevalence of
asthma from the 1920s, supported in part by a grant from the Wellcome Trust.
63 See note 45. 
64 See note 24.
65 Gregg I. (1970) Clinical experience with disodium cromoglycate and assessment of its steroid-sparing action, in
Pepys J, Frankland A W. (eds) Disodium Cromoglycate in Allergic Airways Disease: A symposium held at the Royal
Society of Medicine, London, on 5th March 1969. London: Butterworths, 177–187.
66 Dr Alistair Brewis FRCP (b. 1937) qualified at Newcastle upon Tyne in 1960 and trained at the Royal Victoria
Infirmary, Newcastle, the Hammersmith Hospital, London, the Royal Brompton Hospital, London, and
Manchester Royal Infirmary, before returning to the Royal Victoria Infirmary as Consultant Physician in 1970,
specializing in respiratory medicine. He edited Thorax from 1982 to 1986.
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bronchodilator aerosols and to back up what Ian Gregg has just been saying that many
of us at the time felt that the whole issue was much more complex. I was terribly
impressed by a paper by Speizer, Doll, Heaf and I think Leonard Strang was the last
author, in which they had suspected at the outset that the cause of the deaths might
be overuse of steroids that were getting a bad press at the time. They found to their
surprise that there was relative underuse of steroids in this group of supposedly terribly
severe asthmatics who had died from it. I forget the figures, but there were 177 deaths
that they looked at. I think there were 16 who had been on high-dose steroids, but
the rest had been on either a non- or a low-dose of steroid which hadn’t been put up
or those that had been put up only received the increased dose on the day before
death, something of that sort.67 There was striking underuse of steroids in this group,
so certainly they were pressurized-aerosol users. Perhaps that had given them an undue
sense of security. And the other thing that came up then, and was focused on in other
studies of death, was the element of surprise. Doctors were surprised. That came out
at that time as well. So many people, I think, were not just looking at whether those
who died were being poisoned by the aerosols, but at a much more complex effect of
the bronchodilator aerosols on the rest of treatment and how patients were managed.
Godfrey: I remember the arguments going around at that time, and one I remember
being put forward was that the epidemics were not seen in all countries using the same
drugs, and this was very difficult to explain. I think it was Scotland that had fewer
deaths, that needs to be checked, but I think it was much less in Scotland and greater
in England and Wales.68 This seemed to be regional. Again the similarity to the New
Zealand fenoterol epidemic.69 But in fact that wasn’t correct because it was also seen in
Canada and it was also seen in fact with other bronchodilator drugs when it was looked
at more closely, and I personally think that it comes back again to what you were
saying, the underestimation of the severity of the asthma or masking of the severity of
the asthma or underuse of steroids was almost certainly a major contributing factor
both to the original 1960s epidemic here and to the more recent epidemics.
Clark: Yes, this is déjà vu all over again. I was on the MRC Committee on Asthma Deaths
which went on for quite some time,70 because there was endless debate about the
mechanisms, whether it was the constituent parts of the aerosol other than the
67 Speizer F E, Doll R, Heaf P, Strang L B. (1968) Investigation into use of drugs preceding death from asthma.
British Medical Journal i: 339–343. Information received on 177 out of 184 deaths, revealed that two-thirds of the
patients had received corticosteroids before the terminal episode, and 84 per cent were known to have used
pressurized aerosol bronchodilators. The paper concluded that more information was needed about the usage of
these drugs. See also Speizer F E, Doll R, Heaf P. (1968) Observations on recent increase in mortality from asthma.
British Medical Journal i: 335–339.
68 See Speizer F E, Doll R, Heaf P, Strang L B. (1968), note 67, 337, indicating that the Scottish death rate at ages
5 to 34 was generally lower than England and Wales, but the increase in the number of deaths was similar. See also
Fraser P, Doll R. (1971) Geographical variations in the epidemic of asthma deaths. British Journal of Preventive and
Social Medicine 25: 34–36.
69 See note 51.
70 See note 47.
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pharmacological agents, whether it was the high-strength isoprenaline, whether it was the
hypoxia induced by the use of the inhalers? The whole thing gradually fizzled out as the
epidemic waned. No one was quite sure why it had waned, other than the view that
gradually gained hold, as Alistair Brewis has said, that it was more of a behavioural response
to the treatment. The immediate acute effect on relieving symptoms beguiled patients into
believing that they needed no other treatment, and it was relative undertreatment with
steroids that led to death. And this came up in the recent Saskatchewan study71 of near
death and deaths that were originally related to fenoterol and after endless arguments the
view again came back to the idea that it was asthma being under treated. Indeed
subsequent analysis of the Saskatchewan deaths has shown that when they looked at all the
treatments at the time the odds ratio of death associated with treatment was increased for
virtually all the bronchodilators. It was as high with theophylline as with the others and
the only treatment that was associated with fewer deaths was inhaled steroids, which is now
being followed up. There is now evidence accumulating that regular use of inhaled steroids
is associated with a reduction of deaths in any community. So the whole history of the
original epidemic of deaths has been recycled with New Zealand, Saskatchewan and this
afternoon. I suspect it will continue for another 50 years.
Dr Paul McCarthy:72 I just want to make a comment on the certification of death from
asthma. I think we do need to remember that certification in different countries is at
different levels. I was at a presentation last week on the Scottish Confidential Inquiry into
Asthma Deaths73 and they found that a third of the deaths recorded as asthma were in fact
not from asthma at all, but asthma was on the certificate because the patient suffered from
asthma. To comment on what Professor Clark has said, I think we are in great danger
sometimes of blaming the obvious culprit, and one might say that if a patient is found
dead in a desert clutching a water bottle then they might have died from excess water
intake; and we are in danger of saying, if patients are clutching their empty β-agonist
inhalers, that that is the cause rather than the under-treatment of the underlying disease.
Godfrey: Professor Holgate is a joint author of a paper of age-specific trends in asthma
mortality in England and Wales by Campbell, Cogman, Holgate and Johnston, which
was published in the British Medical Journal in 1997, and that actually shows that
asthma mortality rates are decreasing.74 Do you stand by that, sir?
71 Spitzer W O, Suissa S, Ernst P, Horwitz R I, Habbick B, Cockcroft D, Boivin J F, McNutt M, Buist A S, Rebuck
A S. (1992) The use of β-agonists and the risk of death and near death from asthma. New England Journal of
Medicine 326: 560–561.
72 Dr Paul McCarthy MRCPCH MRCS (b. 1942) was in general practice, first in the Republic of Ireland and
subsequently in Suffolk, from 1974 to 1993. In 1987 he developed the McCarthy mask, the first mask for
attachment to large volume spacers for the administration of inhaled medication to small children. In 1993 he was
appointed Regional Medical Adviser by GlaxoWellcome, later Associate Medical Director from 1997. He is an
Associate Specialist in Respiratory Medicine at the Norfolk and Norwich Hospital, Norwich, and in Paediatric
Respiratory Medicine at Addenbrookes Hospital, Cambridge.
73 Bucknall C E, Slack R, Godley C G, Mackay T M, Wright S C on behalf of SCIAD collaborators. (1999)
Scottish Confidential Inquiry into Asthma Deaths (SCIAD), 1994–96. Thorax 54: 978–984.
74 Campbell M J, Cogman G R, Holgate S T, Johnston S L. (1997) Age-specific trends in asthma mortality in
England and Wales, 1983–95: results of an observational study. British Medical Journal 314: 1439–1441.
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Holgate: Only to the point that the statistics derived from death certificates, if we can
believe them in the UK, show that the number of deaths are decreasing.  If you look
at the age-related mortality, the confidence of a diagnosis of asthma as a cause of death
increases as one gets into the young adults as opposed to the older generation. In this
younger age group the mortality from asthma also seems to be falling and, as far as I
am aware, I think the trends are continuing, which is encouraging. Now whether the
decline in mortality is due to a change in asthma management or the delivery of
healthcare on the ground, we can spend a long time debating, but certainly the trends
are encouraging.
Godfrey: Well, Sir David, could you tell us whether the sales of metered-dose
bronchodilators are decreasing?
Jack: They should not be, because they are key drugs for asthmatics, but as one of
yesterday’s men, I do not really know. I have, however, no doubt that the
proposition being made about under-usage of steroids is right. I used to have the
sad job of sending company doctors to inquests on patients who died after excessive
use of their inhalers. Virtually without exception, the post-mortem results showed
very clearly why they died. Their bronchi were so occluded by the products of
inflammation that no bronchodilator could create an open airway. The only drugs
known to me that can prevent gross physical occlusion of the airways are the
systemic and inhaled anti-inflammatory steroids. There may be others in
development today but I am unaware of them.
Godfrey: Anybody else like to join in? The point I was really making here was that I
am sure that we are not using fewer bronchodilators, in fact we are using even other
kinds of longer-acting bronchodilators. The UK statistics, which I believe are very
good, and Professor Holgate and his colleagues’ data look very solid, show the death
rate at least is not increasing, so someone is doing something better, but we are still
using the bronchodilators.
Sir Christopher Booth:75 I wanted to comment about the pathology of the situation.
When somebody dies of asthma what is the pathology of the bronchioles? I can
recollect when I was a medical student in Dundee many years ago seeing an autopsy
on a patient who died of asthma and the striking thing was the hypertrophy of the
muscle in the bronchioles. There was a gross hypertrophy of the muscles, and one was
puzzled to know how on earth one could conceivably dilate such a situation. I don’t
know what the pathology is in fatal asthma. Anybody like to comment on that?
Godfrey: Well, that has stunned you all into silence.
75 Sir Christopher Booth Kt FRCP (b. 1924) trained as a gastroenterologist and was Professor of Medicine, Royal
Postgraduate Medical School, Hammersmith Hospital, London, from 1966 to 1977 and Director of the Medical
Research Council’s Clinical Research Centre, Northwick Park Hospital, Harrow, from 1978 to 1988, and
Harveian Librarian at the Royal College of Physicians from 1989 to 1997. He was the first Convenor of the
Wellcome Trust’s History of Twentieth Century Medicine Group from 1990 to 1996.
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Holgate: I think there are two important issues here. The event that causes the crisis
leading to death is to do with occlusion of the airway lumen and that is as much about
secretions and air-trapping as it is about contraction of the spiral smooth muscle. But I
think the point you make, Chris [Booth], is a valid one, and it is one which, in our rush
towards the great pro-inflammatory theory of asthma, we have left behind, namely that
in established asthma there are major changes to the structure of the airway wall, referred
to as ‘remodelling’. We are only just beginning to go back and look at the mechanisms
responsible for this now and in particular trying to understand what it is in the asthma
syndrome that leads to this structural change and how this interacts with the
inflammatory components of the disease. 
Godfrey: We would like to move on to talk a little bit about Intal®,76 sodium
cromoglycate and the famous Intal story, because that’s certainly one of the exciting
events of twentieth-century asthma treatment in the UK. I like to think that all the
best inventions in asthma treatment came from the UK and the poor Americans were
years behind. They get very upset when I say that. Mr Bell, can you tell us something
about cromoglycate and Roger?
Mr John Bell:77 I am from Loughborough and I just happened to be an employee of
Fisons Pharmaceutical Division at the time that Intal was being developed, so this is a
bit of a third-party story. The story of sodium cromoglycate, of course, is the story of
Roger Altounyan.78 Roger was a physician at the Monsall Hospital in Manchester where
he had an asthma clinic and another clinic. He had a number of patients that he had
characterized very thoroughly, in fact he could play tunes on them, whatever that meant,
but he really understood this set of patients very well. At the time he was employed by
Benger Laboratories, at Holmes Chapel in Cheshire. The treatment of asthma at that
time of course was by isoprenaline, administered by pressurized inhaler. As we have
already heard this afternoon, the Riker Medihaler was the dominant dosage form I
think. Asthma at that time was a rather mysterious condition and I can remember Roger
describing to me that schoolboys would be told by the headmaster to ‘brace up’, there
was nothing really wrong with them. This seemed to be the picture of the disease at that
time. Roger was looking for a long-acting isoprenaline and he worked with chemists in
the research division, as is well known now, on derivatives of khellin and ultimately they
76 Intal® (disodium cromoglycate, sodium cromoglycate, cromolyn; Fisons) was synthesized in 1965 from khellin,
a chromone that is a derivative of the plant Ammi visnaga. See, for example, Shapiro G G, König P. (1985)
Cromolyn sodium: A review. Pharmacotherapy 5: 156–170.
77 Mr John Bell (b. 1934) was Pharmaceutical Development Manager in Fisons Pharmaceutial Laboratories from
1965 to 1979. 
78 Dr Roger Altounyan FRCP (1922–1987) joined Benger Laboratories, later Fisons Pharmaceuticals,
Loughborough, Leicestershire, as a medical liason officer where he continued his research until his retirement. He
became a consultant chest physician at Monsall Hospital in Manchester in 1957. See Anonymous. (1988)
Obituary: Roger Ernest Collingwood Altounyan. Lancet i: 193. Fuchs E. (1988) Roger E Altounyan. Allergologie
11: 522. Orr T S. (1989) Roger Altounyan: the man and his work. Respiratory Medicine 83 (Suppl. A): 3–6. See
also a 30-minute drama-documentary of episodes from the life of Dr Roger Altounyan entitled Hair Soup,
broadcast in 1992 by Yorkshire Television and produced by Swallow Productions. The part of Roger was played by
David Suchet and Barbara Altounyan, Roger’s daughter, narrated.
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came across sodium cromoglycate, a bis-chromone derivative developed from materials
in khellin. Again I think it is pretty well known that he used to screen these materials on
himself. He’d take the research compound from a nebulizer and then administer his own
antigen, and there are many stories of Roger being found slumped across his desk at
work, whether they are apocryphal or not, I don’t know. One of the features in the
development of Intal, which I think Professor Black79 always reckons to be a good feature
in the development of a drug, is that management stopped the project. Roger continued
working at weekends with a chemist called Colin Fitzmaurice and they moved slowly on
in this research outside company authorization, if you like. 
On the base of his personal use Roger arrived at a dose of about 20mg for this compound,
which exceeded the capability of the pressurized inhaler and Roger was the first person
really to realize the need for coordination – synchronization of dose administration with
inhalation in portable inhalers – and he also is the inventor of the Spinhaler®. He worked
with a colleague in the workshop80 on the thesis of putting a capsule of drug on to a
propeller, so when the propeller rotated the powder was thrown out. I happened to come
across the patents for this recently at this wonderful place just along the road here, the
British Library, where you can read the original patents that were filed in 1963, which is
the same year that the patent on sodium cromoglycate was filed. So Roger effectively
developed both the drug itself, and certainly invented the delivery device. 
About this time [1964], internal in the company, Benger [Laboratories] was taken
over by another Fisons company called Genatosan [in Loughborough]. It isn’t really
enough to discover these drugs, there really has got to be drive behind them from a
management point of view to do it. A young research director called Dr J S G Cox,81
an ex-Glaxo synthetic chemist, took over the project and it was really Jim Cox and
Roger Altounyan who took this through to market. The product Intal was first
marketed in the UK in 1967 which isn’t a bad record, 1963 to 1967 to market, but
the period between 1963 and 1967 was manic inside the company. The drug had to
be synthesized and all the industrial processes scaled up. The mechanism of the
Spinhaler turned out to be complex, and it had to be understood, the design
developed, and the powder technology comprehended.82
79 Professor Sir James Black Kt OM FRCP FRS (b. 1924) was Professor of Analytical Pharmacology at King’s
College Hospital Medical School, London, from 1984 to 1993, later Emeritus. He has been Chancellor of Dundee
University since 1992. He shared the 1988 Nobel Prize for Physiology or Medicine for ‘discoveries or important
principles for drug treatment’ with George Herbert Hitchings Jr (1905–1998) and Gertrude Belle Elion
(1918–1999). 
80 Mr John Bell wrote: ‘Roger approached the problem in his entirely unique way, together with a very resourceful
engineer in the R&D workshop called Harry Howells. Together they essentially developed the prototype of the
current Spinhaler®. Because of the plastic capsule filling problem, the drug was put into standard gelatin capsules.
These were then mounted in a cup at the end of a shaft above a fan blade or propeller, and the shaft mounted on
a pin. Sometimes it worked and sometimes it didn’t.’ Note prepared for the Witness Seminar, 27 March 2000.
81 For biographical details, see note 96.
82 Mr John Bell wrote: ‘We know now that we were working at the limits of powder science in those formulations
and the procedures we developed have continued to the present day in products like the Rotahaler, Accuhaler, and
Turbohaler.’ Note prepared for the Witness Seminar, 27 March 2000.
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The clinical work itself had to be planned and carried out and there are a number of
people in this room who are much more familiar with that side of it than I am. The
regulatory scene itself was undergoing great change, of course, in the wake of
thalidomide, and the Committee on Safety of Drugs83 was just growing up and finding
its feet. The Medicines Act of 1968 was imminent, which changed the nature of drug
development forever. All this work was done prior to getting the drug to market. 
A couple of other just brief points I thought I would mention while talking about
Roger. There was the Fisons setup in Loughborough and round the corner was Riker,
and shortly after Intal was marketed a deputation arrived [at the Derby Road
headquarters of Fisons] from Riker who were of course concerned with the
impingement on their own product, the Medihaler range. They claimed that the
isoprenaline in Intal, which Roger had put in to prevent impact, was actually having
the effect.84 He considered the impact of powder particles on the bronchial walls might
cause bronchospasm. 
The other point about Roger that I thought I would mention was that Roger
vehemently opposed the use of steroids for asthma and he considered it would lead to
Candida overgrowth, but of course I guess we can all be wrong sometimes.85
Milner:86 The first publications on disodium cromoglycate, as it was first known, came
out in a rather topsy-turvy manner in 1967. The first one was by Dr Jack Howell, and
came out in the Lancet in the September.87 In this paper he described a randomized
double-blind study on ten asthmatic adults aged between 30 and 63. Essentially these
ten adults were given inhalations of isoprenaline through a Spinhaler for two weeks,
then for a further two weeks they either had isoprenaline, or they had isoprenaline and
sodium cromoglycate. Then the patients were interviewed weekly, and in addition to
various symptom scores, the clinicians decided whether they were better on treatment
A or on treatment B. All ten were better on treatment with sodium cromoglycate.
The next paper was one written by Dr Cox which came out in Nature and essentially
described the pharmacology and toxicology of the drug, showing that it was very
effective in the animal model, with the exception of the poor old guinea-pig, who
83 See also Tansey E M, Reynolds L A. (eds) The Committee on Safety of Drugs, in Tansey E M, Catterall P P,
Christie D A, Willhoft S V, Reynolds L A. (eds) (1997) Wellcome Witnesses to Twentieth Century Medicine. vol. 1.
London: The Wellcome Trust, 103–132.
84 Mr John Bell wrote: ‘Included in the SCG [sodium cromoglycate] formulation was 100µg of IPS [isoprenaline].
The purpose of this was a concern of Roger’s that impact of powder particles inhaled from the Spinhaler would
produce bronchoconstriction and the IPS was to combat this. Riker argued that this was the actual active
ingredient in the product. Later, when we were confident that RA’s concern was unfounded, the IPS was dropped.’
Note prepared for the Witness Seminar, 27 March 2000. 
85 Mr John Bell wrote: ‘David Jack told me later that the activity of steroids was like a lighthouse beacon compared
with SCG.’ Note prepared for the Witness Seminar, 27 March 2000.
86 For biographical details, see note 27.
87 Howell J B L, Altounyan R E C. (1967) A double-blind trial of disodium cromoglycate in the treatment of
allergic bronchial asthma. Lancet ii: 539–542. See Brewis R A L. (ed.) (1991), note 11, 184–187. 
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apparently got no benefit.88 The only animal that showed really toxic effects was the
dog, who apparently developed bradycardia, hypotension and apnoea but recovered
fairly quickly. But in terms of the safety pattern it was really quite remarkable. You
have to give vast amounts of sodium cromoglycate to harm even the small animals. 
The third paper was the very short paper by Altounyan himself that is just over 200
words. This came out in Acta Allergologica and was essentially describing what we have
already heard about, how he investigated this drug and its apparent effects in blocking
deterioration after inhaling mixed pollens.89
However, after just those three publications, the drug was released. Obviously there
had been a lot of other studies subsequently, but I don’t think there would be many
drugs that would be released nowadays after results on only ten patients had been
reported. Inevitably over the next couple of years, there were a lot of randomized trials
carried out, but it was not until 1970 that we get the first reports on the use of sodium
cromoglycate in children. These were in an edition of Respiration after a number of
investigators were brought together and of the two investigators who spoke English as
their first language, one of them is our current chairman.90 Over the next one to two
years there were a number of different double-blind studies carried out to show that
sodium cromoglycate was indeed an effective drug for use in children and probably
more so than in adults. By the mid-1970s we had comparisons with the inhaled
topical steroids, suggesting that perhaps it wasn’t quite as good. The study which led
to the acceptance of sodium cromoglycate in the States was one our chairman carried
out in combination with Weinberger showing that sodium cromoglycate seemed to be
just as good as theophylline and considerably less toxic.91 But there was then a slightly
odd paper by Dick Jones in 1979,92 in which he claimed that if you looked at
particular sorts of asthmatic children, you could show that sodium cromoglycate was
a mild bronchodilator drug, but I don’t think anybody has managed to show that
88 Cox J S G. (1967) Disodium cromoglycate (FPL 670) (‘Intal’®): A specific inhibitor of reaginic
antibody–antigen mechanisms. Nature 216: 1328–1329. See Brewis R A L. (ed.) (1991), note 11, 188–189. 
89 Altounyan R E C. (1967) Inhibition of experimental asthma by a new compound – disodium cromoglycate
‘Intal’®. Acta Allergologica 22: 487. See Brewis R A L. (ed.) (1991), note 11, 183. Professor Anthony Milner wrote:
‘This article describes how a large number of compounds were investigated for their antiasthma effects by one
investigator (Roger himself ) who at three- to four-day intervals inhaled the test drugs prior to inhalation of mixed
pollen antigens which normally produced a 45 per cent reduction in forced expiratory volume in one second
(FEV1). Intal was identified as a drug that was highly effective, producing a 70 per cent reduction in fall in FEV1
at a dose of 1mg, and a 40 per cent reduction at 0.15µg. [See note 100, 767, for details.] He recommended the
use of 20mg six hourly. He also stated that the compound was ineffective if given after the challenge. Despite the
fact that data had only been published on ten patients, Intal was launched later that year.’ Notes prepared for
Seminar, 4 April 2000.
90 Godfrey S. (1970) The physiological assessment of the effect of disodium cromoglycate (DSCG) in the
asthmatic child. Respiration 27 (Suppl.): 353–356.
91 Hambleton G, Weinberger M, Taylor J, Cavanaugh M, Ginchansky E, Godfrey S, Tooley M, Bell T, Greenberg
S. (1977) Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma.
A collaborative study. Lancet i: 381–385.
92 Chung J T, Jones R S. (1979) Bronchodilator effect of sodium cromoglycate and its clinical implications. British
Medical Journal ii: 1033–1034.
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again. Anyway over this period sodium cromoglycate had gained a reputation that it
was an effective drug in all except severe asthmatic children and was very safe. So when
the asthma guidelines began to be developed both nationally and internationally
sodium cromoglycate had a very strong place at stage 2, that is if you couldn’t control
the patient on just the occasional dose of a β2 agonist, they ought to be on sodium
cromoglycate. They ought also to have been shown to have failed on sodium
cromoglycate before they went on to the next level. And it’s only really in the very
latest of the guidelines93 that things are now beginning to change, so that now we are
given an option of either having sodium cromoglycate or low-dose inhaled steroids as
our first prophylactic level. I think the reason for this is partly that sodium
cromoglycate isn’t always effective, it has to be taken at least three or four times a day,
and is less pleasant to take. Now just one or two other bits of information about Roger
Altounyan. Apparently he was dyslexic and had a lot of problems at school, and this
has been put forward as an explanation why perhaps his article was only 200 words
when it was such an important topic. He also, as I am sure everybody in this room
knows, was part of a family who used to go on sailing holidays in the Lake District
and there he met up with Arthur Ransome,94 and became Roger in the stories. But I
don’t know whether the rest of the family also have those funny names or not. 
Finally in addition to developing the Spinhaler, as far as I can make out he was the
first one who actually used hypotonic solution for generating broncho constriction. I
found a nice paper by him on this topic.95 But he was a remarkable man and I am sure
a lot of us remember him with a lot of affection.
Godfrey: I also remember Roger with great affection, he was one of my favourite
people, a most extraordinary man, with bad asthma, who used to suck away on his
Spinhaler which did him absolutely no good at all although he insisted it was
wonderful and I used to say, ‘Why don’t you just take some steroids?’ No, no, he
would suck on his Spinhaler and wheeze away. A few years ago there was a meeting in
Jerusalem, he grabbed hold of me and he said, ‘This is boring, get in your car, I want
you to take me to see where I lived’. I said, ‘What do you mean?’ He said that during
the Second World War his father was stationed in Palestine as it was then with the
British Forces and Roger was a young man, he must have been a teenager and they
lived for a while in Jerusalem. I said, ‘With pleasure’ and so we got in the car and I
said, ‘Well, where is it?’ He had never been back since, this must have been probably
40 years later and he said, ‘Well, first of all go to the railway station’. So we drove to
the railway station and he said I think you take that fork and then we go left and we
93 British Thoracic Society. (1997) The British guidelines on asthma management. Thorax 52 (Suppl. 1): S1–S21.
A table on the management of acute severe asthma in general practice is reproduced from this article in section 3
on the respiratory system in the British National Formulary, published by the British Medical Association and the
Royal Pharmaceutical Society of Great Britain.
94 Ransome A M. (1930) Swallows and Amazons. Jonathan Cape: London.
95 Schoeffel R E, Anderson S D, Altounyan R E. (1981) Bronchial hyperreactivity in response to inhalation of
ultrasonically nebulized solutions of distilled water and saline. British Medical Journal 283: 1285–1287.
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came to some crossroads, and he said, ‘I am sure this used to be a roundabout’. He
said, ‘Take the third exit’ and he said, ‘There it is’ and we stopped outside this house
and the owner of the house came out, very suspicious, because there were these two
sort of prowlers prowling around outside their house and I explained what it was and
that seemed to satisfy her. Also at the time my children were much younger and they
were fascinated to meet Roger of Swallows and Amazons, and they thought he looked
a bit strange for a little boy. Who else would like to chip in? Please, yes. One of the
heroes of the story.
Dr Jim Cox:96 I wanted to add one or two comments on the development of Intal.
One for me was a very salutary lesson in the importance of the basic scientist sitting
in on clinics. I remember one of the early trials on Intal and I was talking to the
clinician and he called the child and his mother in and I said, ‘Well, how did you find
the result?’ ‘Oh a wonderful drug, very good’. I then said, ‘Well, what about the
Spinhaler? Did you have any difficulty with that?’ The child looked at his mother and
neither knew what to say, as they hadn’t been given the Spinhaler, they had just taken
the capsule as it was. There was no way that they could have got a result. The other
comment also relates to the development of Spinhaler, because in many ways more effort
was put into that, than into the development of the actual drug. We were very
determined that the Spinhaler should be as efficient as possible and it so happened that
the professor in the Department of Aeronautical Engineering in Loughborough was very
keen on this and he looked at the Spinhaler and did various measurements of it. He said,
‘The propellers are round the wrong way, you will have to turn it round,’ that it couldn’t
possibly work as it was. We spent a long time doing this and tried it out again and it just
didn’t work at all. So I think the importance of this is that sometimes you have to bear
in mind that there are many other factors that come into play in the development of a
drug, it is not always objective and clear as the battle we have described.
Godfrey: Professor Silverman was my research fellow who did all the work for which
I took the credit on the trial of Intal in children.
Silverman: Yes, that’s quite true, that’s where I started my life in respiratory paediatric
medicine, with Simon [Godfrey] who was my boss and has remained so ever since. I
just want to make a general point, because it is quite intriguing how a number of
drugs, such as theophylline and Intal (sodium cromoglycate), have been thought to
have their beneficial effects in asthma by a particular mechanism, only later to be
shown to have effects which differ, and which may well explain their antiasthmatic
benefits. It’s intriguing how a number of drugs have evolved in asthma by trial and
error and the explanation for their benefit has been based on some associated
pharmacological effect which may or may not be the correct one. I don’t know
96 Dr Jim Cox (1931–2001) was Director of Research and Development at Fisons Pharmaceuticals from 1963 to
1978. He retired in 1999. See Cox J S G. (1970) Review of chemistry, pharmacology, toxicity, metabolism, specific
side-effects, anti-allergic properties in vitro and in vivo of disodium cromoglycate. In op. cit. note 65, 13–25. See
also Cox J S G, Beach J E, Blair A M J N, Clarke A J, King J, Lee T B, Loveday D E E, Moss G F, Orr T S C,
Ritchie J T, Sheard P. (1970) Disodium cromoglycate (Intal). Advances in Drug Research 5: 115–196.
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whether that problem still exists, because there is now a resurgence of interest in
obtaining drugs from various plants around the world and trying them out in various
ways. This does have disadvantages, for example one of the sidelines was that which
followed as a result of the work on Intal and its potential effect in stabilizing mast
cells, which seems, as far as I can see, to have been a dead end. The original
mechanism by which it had its effect led to the screening of vast numbers of other
drugs, using that particular mechanism, to try to determine or identify antiasthmatic
drugs. I suppose that history possibly continues to repeat itself in the way in which
drugs continue to be screened as a result of effects that may not be relevant in their
clinical benefits. 
Godfrey: Does anybody here now believe or disbelieve that chromones and
cromoglycate works by inhibiting mediator release from mast cells?
Holgate: There’s little doubt that it works by inhibiting mediator release from mast
cells, but this may not be its only mechanism of action. Sodium cromoglycate is now
known to activate particular phosphorylation pathways in the mast cell which are
intimately related to the degranulation processes. It has been suggested that sodium
cromoglycate interferes with a chloride channel present not only in mast cells but also
in other cells such as epithelial cells.97 Its highly acidic and hydrophilic properties
imply that it works on the cell surface, but the precise molecular target still has not
been defined. I absolutely agree with the comments you made earlier, that sometimes
one believes one has identified a critical mediator or a pathway that is involved in
asthma pathogenesis but further research proves this not to be the case. A good
example of this is platelet-activating factor (PAF), receptor antagonists which wasted
a huge amount of resources in the pharmaceutical industry, based on animal studies
and not understanding the complexities of human disease. So I would agree entirely
with the comment, but I wouldn’t like the record to go unmarked saying that this drug
has no effect on mast cells – it does. 
Godfrey: Well I would just like to come back to the paper by Silverman and Andrea
– Andrea was our lab technician – showing that cromoglycate inhibited exercise-
induced asthma only if you gave it before the exercise, but not if you gave it at the end
of the exercise yet before the attack had developed. And I wonder how you could relate
that to its effect, other than by releasing mediators from something?
Silverman: It seems reasonable to assume that because it has to be given before the
challenge, before the effect of that challenge has developed, that it probably doesn’t
work by some sort of neurological mechanism which would be more likely to be
relatively rapid, (although there are some neural actions of sodium cromoglycate). I
think that the hypothesis that it blocks the release of some sort of mediator is probably
the correct one. But I have to say that I think that the attempt to screen lots of other
97 Holgate S T, Davies D E, Lackie P M, Wilson S J, Puddicombe S M, Lordan J L. (2000) Epithelial–mesenchymal
interactions in the pathogenesis of asthma. Journal of Allergy and Clinical Immunology 105: 193–204.
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drugs for their effect in inhibiting mast-cell release of histamine and various other
agents has seemed in practice not to lead very far. I think that that may not be its
principal beneficial effect in asthma.
Godfrey: How do you think the antileukotriene drugs work, if they do work?
Holgate: They are highly selective receptor antagonists or inhibitors of leukotriene
production. Leukotrienes are the components that comprise a slow-reacting substance
of anaphylaxis (SRS-A) that is released by inflamed asthmatic airways and originally
was described by Feldberg and Kellaway in 1938.98
I am glad you mentioned that because Roger Altounyan was the first person to
describe the clinical use of an antagonist to slow-reacting substance of anaphylaxis
(SRS-A) in 1958, following a paper he heard in 1956 by Walter Brocklehurst99 who
had been working at Mill Hill at the time with Sir Henry Dale and Frank Austin. This
was before he [Altounyan] made the dichromone, using the single agent. When
administered to himself, he showed that a new chemical entity, K18 (which was
structurally derived from khellin extracted from the seeds of the Mediterranean plant
Ammi visnaga) inhibited the immediate bronchoconstriction triggered by inhaled
allergen. He further showed addictive inhibition with mepyramine when combined
with K18.100 Although Dr Altounyan gave K18 to 25 outpatients and showed efficacy
in asthma, this development had to be discontinued on account of hepatotoxicity. This
was the first description of the clinical use of an SRS-A (or cysteinyl leukotriene)
antagonist and was the precursor of the classical in vitro SRS-A antagonist FPL55712
as well as part of the search that eventually led to the discovery of sodium cromoglycate. 
Howell: Could I first say that there is a widely held misconception that Roger
[Altounyan] invented the Spinhaler to deliver Intal. I am almost certain this was not
the case. He told me that he invented it several years earlier in the late 1950s to deliver
another therapy by inhalation, a mixture of pancreatic enzymes called Lomulase101 for
the treatment of chronic bronchitis. He had the idea that if a chronic bronchitic
inhaled these enzymes – trypsin and chymotrypsin – they might help to liquefy the
98 Feldberg W, Kellaway C H. (1938) Liberation of histamine and formation of lysocithin-like substances by cobra
venom. Journal of Physiology 94: 187–226. See also Feldberg W. (1954) Review Article: On some physiological
aspects of histamine. Journal of Pharmacy and Pharmacology 6: 281–301. 
99 Brocklehurst W E. (1956) A slow reacting substance in anaphylaxis – ‘SRS-A’, in Wolstenholme G E W,
O’Connor C M. (eds) Histamine: Ciba Foundation symposium jointly with the Physiological Society and the
British Pharmacological Society, held at the Ciba Foundation, 6–7 April 1955, in honour of Sir Henry Dale.
London: Churchill, 175–179. Brocklehurst’s thesis, entitled ‘The formation and release of a slow-reacting
substance in the course of the anaphylactic reaction’ was completed in 1958.
100 See Edwards A M, Howell J B L. (2000) The chromones: history, chemistry and clinical development. A tribute
to the work of Dr R E  Altounyan. Clinical and Experimental Allergy 30: 756–774.
101 Mr John Bell wrote: ‘Benger had already developed and marketed a device called the Lomuliser, a bulb-operated
powder inhaler, with IPS [isoprenaline] in competition to Medi-haler. This was a difficult device to manufacture.
The drug was contained in plastic capsules, filled on a special machine devised and built by the Chief Engineer,
Frank Wright.’ Note prepared for the Witness Seminar, 27 March 2000.
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sputum and make it easier to expectorate. These enzymes were readily available
because they were the ‘bread and butter’ of the Benger Company for the preparation
of the predigested protein food, Benger’s Food. He tried it out in a test tube and
showed that they would liquefy sputum from chronic bronchitics. His next task was
to deliver the powdered enzymes in quite large quantities into the bronchi of chronic
bronchitics. My understanding is, and this was from him, that he invented the
Spinhaler to deliver this.102 Unfortunately the research director had his own idea about
how the enzymes should be delivered, and it was not by the Spinhaler. So it was put
to one side, but clearly it was resurrected subsequently, for the FPL670 [Intal]
administration, if the patent was taken out in 1963. But I don’t think many people
realized that. They associated him with Intal and the Spinhaler. 
I had the immense good fortune to meet Roger in 1961 in Manchester where we were
both based at that time and he told me about the work that he had been doing at
Benger’s over the previous four or five years.103 I have to confess that my interests were
more physiological and I listened, but I did not get enthusiastic. In 1963 he
telephoned me to say that he had now tried out on himself this new compound he’d
been trying to develop and it had all of the properties that he was looking for. The
question he was really interested in now was if this [Intal] inhibits the allergic reaction
that follows the inhalation of an antigen, how might one use it therapeutically in a
patient with asthma? We talked about this on the phone and later together, and
decided that since he had shown that, for the compound to be effective it had to be
delivered before the antigen, the only way to test its efficacy was to administer the
drug continuously for as long as possible, even though it was impractical as a
treatment. The first thing to establish was ‘did it work?’ 
He had a red-haired Irish patient with very severe disabling, chronic asthma requiring
high doses of corticosteroids who was prepared to try anything. We took him into one
of Sir Douglas Black’s104 beds in the Manchester Royal Infirmary one Friday night, put
him into an oxygen tent over the weekend and nebulized the new compound into it
continuously for 72 hours. On the Monday morning when we finally took him out
of the tent the result was unequivocal: it had done absolutely nothing. Roger was
intensely disappointed. He went back to his lab at Monsall, tested it again on himself
and it didn’t work at all. He went back to Benger’s at Holmes Chapel [Cheshire] to
discover that they had had to make a new batch, the first batch had been used up or
thrown away or something, and this new batch just didn’t work and nobody knew
102 Professor Jack Howell wrote: ‘The idea of the Spinhaler came to him when he remembered sitting in his Spitfire
with the propeller whirring in front of him.’ Letter to Mrs Lois Reynolds, 1 April 2001. See also note 80.
103 Professor Jack Howell wrote: ‘This was based on what he had noticed in a series of in vitro studies carried out
since 1957 by his pharmacologist colleagues who were attempting to synthesize a better bronchodilator
preparation.’ Letter to Mrs Lois Reynolds, 1 April 2001.
104 Professor Sir Douglas Black Kt FRCP FRCPath FRCPsych FRCOG (b. 1913) was appointed to the Department
of Medicine at Manchester University in 1946, becoming Professor of Medicine from 1959 to 1977, later Emeritus.
He was Chief Scientist at the Department of Health and Social Security from 1973 to 1977, a member of the MRC
from 1966 to 1970 and 1971 to 1977 and President of the Royal College of Physicians from 1977 to 1983.
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why. Roger’s reputation with top management, quite unfairly, had not been high but
was now even worse and about this time support for the project was withdrawn.
Fortunately he still had the confidence of the pharmacologists and chemists who were
willing to work unofficially in continuing to synthesize new compounds. Jim Cox will
correct me if I have the details wrong, but I understand that for a time because of these
problems they had to work in relative secrecy until in 1965,105 in early February, he
rang me up again to say, ‘I have got it, it really does work’106 and that was FPL670, the
670th compound and chemically it was disodium cromoglycate.
He gave me some to try on a couple of patients of mine, just two of them. Both
improved symptomatically, but only one of them had improvement in lung function
tests and this had a profound effect upon me and the way in which we designed the
subsequent double-blind cross-over trial, which has been referred to.107 The next thing
was to persuade the company that they had something good. Roger had been
associated with two projects soon after he joined the company in 1956. In the first,
he was given the project to study the ability of the iron-dextran compound, Imferon,
to prevent anaemia in rapidly growing piglets and hence to improve their rate of
growth. While it prevented anaemia, unfortunately it did not improve their growth
rate and therefore was not commercially useful. He felt he was blamed for this result.
I already mentioned the second project involving the inhalation of pancreatic enzymes
for the treatment of chronic bronchitis. Before the drug was launched into clinical
practice, a number of trial patients developed severe asthmatic reactions and he
advised the delay of its launch. But this was not done and it had to be withdrawn
within months.
Roger knew that he did not carry the confidence of many senior people in the
company, and that there might be difficulties in persuading them to pursue the
development of disodium cromoglycate. They had recently appointed a new research
director, Dr James Cox, and it was vitally important to convince him that this was a
drug worth pursuing. Roger asked me if I would go with him to see Jim Cox and we
went to Holmes Chapel. What I remember most vividly was the thickness of the pile
of the carpet and the young Dr Cox behind his large desk. I can remember saying to
him finally that using this drug reminded me of the introduction of corticosteroids. I
don’t know what his thoughts were, but the response was enthusiastic. I asked if we
105 Professor Jack Howell wrote: ‘Roger wondered if some highly active “contaminant” had been synthesized
inadvertently on the first occasion, and one of the chemists suggested that two of the molecules might have joined
together to form a bis-chromone. So they deliberately made a bis-chromone which Roger tried out on himself in
January 1965.’ Letter to Mrs Lois Reynolds, 1 April 2001.
106 Professor Jack Howell wrote: ‘Roger found it completely blocked the asthmatic reaction which followed
inhalation of extracts of guinea-pig hair or grass pollens, even when taken four hours before the challenge, but
rapidly lost its effectiveness if it was inhaled after the challenge. He himself continued to inhale the compound
four times a day with substantial clinical improvement and he was able to lower his daily dose of prednisolone. He
gave the new compound to half a dozen of his severely asthmatic patients with similar improvement.’ Letter to Mrs
Lois Reynolds, 1 April 2001.
107 See note 87.
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could have more of the compound to do a formal controlled study – this mammoth
study on ten patients that was referred to earlier – and he agreed. His decision was
absolutely crucial to the development of cromoglycate, because he had the capacity at
that point to say ‘Run away little boys, don’t waste my time’ as I think some other
people were tending to do before that. We owe a lot to Jim Cox for immediately seeing
the potential of the drug and his enthusiastic support which led to the drug being
available for clinical use only a few years later.
One further episode that sheds light on Roger’s character: he wanted to know what
happened when cromoglycate was given intravenously and he asked me if I would
inject him with it. I refused. But he was very persistent and said he had tried it on
pretty well every animal species without adverse effect, but admitted that they hadn’t
tried it on primates. A few months later he said they had now given it intravenously
to a marmoset without ill effect and would I please give him the injection. I felt I
could resist no longer and with considerable reluctance agreed. He came to our clinical
room at the Royal Infirmary where first he did skin tests on himself, blew into the
spirometer to measure his forced expiratory volume in one second (FEV1). He lay on
the couch, I then attached ECG leads and a blood pressure cuff and started a slow
injection. Roger said I gave him 12mg, my recollection was 7mg. For about half a
minute nothing appeared to happen but then he said in quick succession, ‘I’m feeling
something on my skin, my face is burning, I’m burning all over’. His pulse rate and
blood pressure went up, so did mine. But the burning sensation quickly subsided and
Roger jumped off the couch, repeated his skin tests and measured his FEV1 as if
nothing happened. Later I told Roger jokingly, that my main concern was what I was
going to say to his wife Hella and he embellished this to ‘Hella, I’m afraid I have killed
Roger – with some of his own medicine’. There is no doubt that I was foolish to agree
to do it, but Roger was a very persuasive, very courageous, absolutely single-minded
man and I wonder how many of you in this room would have been able to refuse to
give that injection to him. 
Cox: I must make one comment. I don’t remember the depth of the carpet, but those
of you who know Jack [Howell] very well, it’s very difficult to say no when he asks
for something.
Godfrey: I am glad that you mentioned its number I have been trying all day to
remember what it was called, FPL-something or other, because when Tim [Clark] and
I must have been housemen or registrars around the Hammersmith at that time, even
Moran Campbell tried some of this stuff on some asthmatics who were doing exercise
tests. I don’t think it worked at all, but that had to be something special. 
Howell: Can I come back on one little point? As some of you may know Roger had
extensive atopic eczema, but he didn’t have his first attack of asthma until 1950, when
he was a medical student. This frightening attack happened one night and recurred
the following night. So he went to see the Casualty Medical Officer at the Middlesex
Hospital, who after diagnosing asthma proceeded to test his knowledge of its causes,
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eventually adding, pointing to his temple, the psyche. Roger was not impressed with
its implication. This young doctor went on to become a very distinguished respiratory
physician, Dr Moran Campbell.108
Godfrey: Well, this has been fascinating. I would like to ask Sir David Jack to
introduce the discussion or reminiscences concerning another British invention, the
salbutamol story, Ventolin.
Jack: I too knew Roger Altounyan and well remember a hilarious lecture he gave in
York about how he developed ‘Intal’ despite everything his management would do to
stop him. I was luckier. I can say in all honesty that I did not lack support from
management in Allen & Hanburys or in Glaxo. The pattern was set during one of the
early conversations I had in 1962 with C W Maplethorpe,109 the man who hired me as
Research Director of Allen & Hanburys. A member of the Glaxo Board, he was a great
man but also very impatient. I had found that there was not a single viable project in
the research portfolio and, after a while, I went to see him to explain what I wanted to
do. Within two minutes he held up a hand and said, ‘David, I don’t care what you do
so long as you are successful.’ I acted on that basis for the next 26 years in Glaxo.
Today I want to outline some highlights of the development of selective β-adrenergic
and anti-inflammatory steroid activities in the lung. First, however, I would remind
you of what Ehrlich,110 the greatest-ever drug hunter, had to say about drug discovery.
The three essentials were: sound, practicable, original ideas; money to pay for the
required resources; and luck. As I outline how salbutamol and other products were
found, you will find that all three played their part.
Our first asthma research objective was a long-acting analogue of isoprenaline for use
by inhalation. Isoprenaline is, of course, an extremely effective but short-acting
bronchodilator. It was also a dangerous drug because patients used it increasingly
despite worsening asthma. The key idea came from Larry Lunts,111 a senior medicinal
chemist with a Midas touch in research. He decided to make non-catechol analogues
of isoprenaline because the cause of its brief effect is inactivation in the body by
mechanisms that are catechol specific.
Unfortunately the chemistry proved to be difficult and it was not until 1966 that
AH3021, the saligenin analogue of isoprenaline, was first tested in the pharmacology
108 For biographical details, see note 6.
109 See Tweedale G. (1990) At the Sign of the Plough: 275 years of Allen & Hanburys and the British pharmaceutical
industry, 1715–1990. London: Murray. See also Davenport-Hines R P T, Slinn J. (1992) Glaxo: A history to 1962.
Cambridge: Cambridge University Press. Jones E. (2001) The Business of Medicine: The extraordinary history of Glaxo,
a baby food producer, which became one of the world’s most successful pharmaceutical companies. London: Profile Books.
110 Professor Paul Ehrlich (1854–1915) won the Nobel Prize in Physiology or Medicine in 1908 for his work on
immunity. See Himmelweit F. (ed.) (1956–60) The Collected Papers of Paul Ehrlich. Four vols. London: Pergamon Press.
111 Hartley D, Jack D, Lunts L H C, Ritchie A C. (1968) New class of selective stimulants of β-adrenergic
receptors. Nature 219: 862.
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laboratory. The primary tests were done by a new graduate, Valerie Cullum (now Valerie
Alabaster) who is now head of cardiovascular research in Pfizer Research. Very soon
Valerie reported to Roy Brittain, head of pharmacology, ‘This is a funny β-agonist. It is
pretty active on bronchial muscle but is virtually inactive on the heart’. Roy replied, ‘That
cannot be right. Go and do it again.’ This she did with the same result and Roy still
sceptical then did the tests himself. Thus it was that we stumbled upon the first highly
active, highly selective β2-adrenoceptor stimulant.112 The truth is that the drug really
found us, surely the kind of luck that Ehrlich spoke about. The next member of the series
was salbutamol (AH3365), which is more active at β2-receptors and even more selectively
acting on bronchial muscle. First made in 1966 it was marketed in 1969 as the ‘Ventolin’
inhaler and in time became the most prescribed bronchodilator in the world.
I have regularly been asked how we managed to market salbutamol only three years
after its first synthesis. The simple answer is that in the early stages we experimented
on one another, a procedure that I commend to all responsible for recommending new
medicines to other people. I was first to take salbutamol by inhalation and by mouth
under the supervision of Wilfred Simpson, a bold and intelligent clinical
pharmacologist, who was then our medical director. He had the drug next under my
supervision! Salbutamol was obviously innocuous in us but neither of us is asthmatic.
The first asthmatic to take salbutamol was Desmond Poynter, our friend and
colleague, who was head of pathology. Desmond had unwisely told me that he was
very sensitive to sulphur dioxide. Since he knew more than anybody else about his
condition and the toxicology of salbutamol, I had no hesitation in inviting him to
inhale a small amount of sulphur dioxide to see if inhaled salbutamol relieved
bronchoconstriction. Desmond readily agreed and we soon established that
salbutamol is an effective bronchodilator with minimal cardiovascular side-effects. 
In the next stage, Colin Dollery113 agreed to test the effects of salbutamol on two
asthmatic volunteers in his ‘body box’114 at the Hammersmith. The volunteers were
Anne Ruffel and Graham Williams who were researchers in Allen & Hanburys.
Within a month we knew the effective doses of salbutamol, by inhalation and by
mouth, the duration of the action and the probable use-limiting side-effects. Thus it
took only six months from the date of first synthesis to establish the probable
efficiency and safety of the drug. Today that would take at least two years which, in
my view, is an unnecessary self-inflicted wound.
When we knew that small inhaled doses of salbutamol gave near-maximal
bronchodilation for three to four hours without use-limiting side-effects we asked
112 Brittain R T, Farmer J B, Jack D, Martin L E, Simpson W T. (1968) α-[(t-Butylamino) methyl]-4-hydroxy-m-
xylene-α1, α3-diol (AH3365): a selective β-adrenergic stimulant. Nature 219: 119–120. Refers to unpublished
work of J B Farmer, V A Cullum and G P Levy on aerosolized acetylcholine.
113 For biographical details, see note 48. 
114 For a historical review of the whole-body plethysmograph, see Comroe J H Jr. (1977) Man-Cans. (Conclusion).
The body plethysmograph (body box). American Review of Respiratory Disease 116: 1091–1099.
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ourselves how similarly selective glucocorticoid activity might be achieved in the
lungs. Wilfred Simpson provided the answer.
Wilfred reasoned that the airways in asthma are simply another inflamed body surface
and might, therefore, respond well to potent anti-inflammatory steroids of the kind
used to treat eczema, psoriasis and other skin diseases. Their most serious side-effects
in dermatology are ‘thinning’ of the skin and, if used on large areas of the skin,
systemic glucocorticoid activity.
The essential properties of a selectively acting topical steroid were thought to be (i)
persistent binding to glucocorticoid receptors in the lung, (ii) lack of adverse effects
on the lung and (iii) low oral bioavailability because at least 80 per cent of every
inhaled dose is swallowed.
By great good fortune, beclomethasone dipropionate (BDP),115 the only potent topical
steroid readily available to us, proved to have the necessary characteristics. It had been
made available to us by Glaxo Research for the ‘Propaderm’ topical steroid products.
We already knew it to be about 600 times more active than cortisol acetate in the
McKenzie skin-blanching test,116 which measures the intensity of binding to
glucocorticoid receptors in the skin. We then established that the lungs were not
adversely affected in dogs made obviously ‘Cushingoid’117 by repeated daily inhalations
of large doses of BDP for 12 weeks. This reassured us that the drug would probably
be safe in man. Our next step was to assess the oral bioavailability of BDP by
measuring reductions in early morning plasma cortisol levels after oral and
intravenous administration of the drug to ourselves. It was about five times more
active by the intravenous route and so its bioavailability was only about 20 per cent.
Exploratory open clinical trials of the BDP inhaler were carried out in Ian Grant’s unit
in Edinburgh118 and later in Harry Morrow Brown’s clinic in Derby.119 The Edinburgh
results were at best equivocal. However, Harry resolved our doubts in a remarkable
clinical publication in the British Medical Journal.120 I will say no more about this
because Harry [Morrow Brown] is here in person and more than able to speak for
himself. I am most grateful for all he did.
115 Beclomethasone dipropionate (Becotide; Allen & Hanburys) was put on the market in 1972.
116 The McKenzie skin-blanching test is commonly used to evaluate the biochemical potency of topical corticosteroids.
See McKenzie W A, Stoughton R B. (1962) Method for comparing percutaneous absorption of steroids. Archives
of Dermatology 86: 608–610.
117 Symptoms and signs of Cushing syndrome are caused by an excess of cortisol hormone. See Cushing H. (1932)
The basophil adenomas of the pituitary body and their clinical manifestations. Bulletin of the Johns Hopkins
Hospital 50: 137–195.
118 Choo-Kang Y F, Cooper E J, Tribe A E, Grant I. (1972) Beclomethasone dipropionate by inhalation in the
treatment of airways obstruction. British Journal of Diseases of the Chest 66: 101–106.
119 For biographical details, see note 124.
120 Brown H M, Storey G, George W H S. (1972) Beclomethasone dipropionate: A new steroid aerosol for the
treatment of allergic asthma. British Medical Journal i: 585–590.
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The BDP inhaler was marketed as ‘Becotide’ in 1972. It was generally well received,
but its use was reserved for patients inadequately controlled by bronchodilators or
theophylline. Indeed, it took nearly 20 years for inhaled BDP to be accepted as a safe
primary treatment for asthma. Amazingly, at that very time after 30 years of clinical
experience, regular use of inhalers containing selective β2-agonists, the standard
primary treatment, was reported to be unsafe because it caused the asthma to worsen!
More of this anon.
During the 1970s all our efforts to find better treatments for asthma failed. When I
assessed the situation in 1981 the patents on salbutamol and BDP were uncomfortably
close to expiry. I, therefore, decided that our best option was to try to improve the
drugs we already had. The only obvious fault with inhaled salbutamol is that its
duration of action is not long enough to persist throughout the night. A truly long-
acting alternative was clearly a worthwhile objective. Similarly, the only obvious
weakness with BDP treatment was weak systemic glucocorticoid side-effects associated
with high dosage with the drug. A more selectively acting BDP was required.
To obtain a long-acting β2-agonist for use by inhalation I asked my colleagues to make
a β2-agonist which would bind irreversibly to its receptor protein, because I expected
its duration of action to be determined by the life of the occupied receptors. Others
were less sure because of the vast literature on desensitization of continuously activated
β receptors. If the literature was right, my occupied receptors would be rapidly
desensitized. In the event, the required drug [salmeterol] was found by replacing the
N-substituent of salbutamol by a long flexible nonpolar chain.
Salmeterol did bind irreversibly to the β2-adrenoreceptor protein and was found by
Nils Svedmyr and his colleagues121 to be effective for at least 12 hours when inhaled
by asthmatic patients. All subsequent studies confirmed this, and also that repeated
doses did not induce tolerance. When I retired from Glaxo in 1987, I was convinced
that the pharmacological effects of salmeterol and BDP are synergistic and,
administered concurrently, that they would provide a new better way to treat
asthma.122 Unfortunately it took more than ten years for this possibility to be realized.
Improving on BDP proved to be relatively easy. I simply chose fluticasone propionate
(FP) from the Glaxo library of steroids, because it had been found to be about twice as
active as BDP in the McKenzie test in man, but virtually inactive as a glucocorticoid
after oral administration to mice. That was very unusual because the mouse was known
to be exquisitely sensitive to oral glucocorticoids. My choice dismayed the director of
chemistry, Barry Price, because FP was very difficult to make! The reason why FP is
121 Ullman A, Svedmyr N. (1988) Salmeterol, a new long-acting inhaled β2 adrenoceptor agonist: comparison with
salbutamol in adult asthmatic patients. Thorax 43: 674–678. See Brewis R A L. (ed.) (1991), note 11, 215–219. 
122 Sir David Jack wrote: ‘This was stated explicitly in my 1988 Centre for Medicines Research Lecture. “In my
view, the combined use of these drugs will greatly simplify treatment and satisfactorily control asthma in the great
majority of patients”.’ Comment on draft transcript, 15 January 2001. See Jack D. (1989) The challenge of drug
discovery. Drug Design and Delivery 4: 167–186.
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inactive in the mouse was soon found to be quantitive inactivation by first-pass
metabolism in the liver and, fortunately, human beings dealt with it similarly. Products
containing FP are now being increasingly used instead of BDP and similar steroids.
I regret that I have to finish by expressing my concern at how long it has taken for
the value of concurrent treatment with a long-acting β2-agonist and a topical steroid
to be recognized and accepted. Much of the delay resulted from the 1990 report by
Sears and his colleagues123 that regular inhaled β-agonist treatment caused asthma to
worsen. They warned against such treatment and recommended the use of such
inhalers only when necessary to relieve acute symptoms. That these
recommendations were immediately incorporated into the Guidelines for Asthma
Treatment was surprising because their finding was based on a total of 56 assessable
patients and was at odds with the results obtained in many larger, well-controlled
studies, and with more than 20 years of experience with inhaled β2-agonists. I very
much hope that concurrent use of a long-acting β2-agonist and a potent anti-
inflammatory steroid by inhalation will be used increasingly by adult asthmatics and
investigated further in children because it may prevent or reduce irreversible damage
to the airways. The shadow of Sears’s recommendations is still all too obvious in the
guidelines for asthma treatment.
Godfrey: Thank you very much. When did beclomethasone become easily available
on the market?
Jack: We started the work in 1966 and the inhaler was first marketed in the UK in 1972.
Godfrey: I was trying to remember with Professor Silverman the first patient I treated
with beclomethasone. The first child was a little West Indian boy and he was a quite
troublesome asthmatic, and we came to the conclusion that it didn’t work at all,
because we gave him 50 micrograms once a day or something like that. But
subsequently, as you know, we found that it was quite a good drug. 
Dr Harry Morrow Brown:124 Well my story also has a lot of luck in it. It begins over
50 years ago, because in my MD thesis I proposed that allergic reactions should be
regarded as manifestations of incomplete adaptation to the environment, or adaptive
dysfunction. There was no opportunity to pursue this concept further in an NHS in
its birth pangs, and a scramble for jobs, in which I was lucky to get a job as full-time
consultant to a decrepit chest clinic in Derby in 1953, dealing mainly with
123 Sears M R, Taylor D R, Print C G, Lake D C, Li Q Q, Flannery E M, Yates D M, Lucas M K, Herbison G P.
(1990) Regular inhaled β-agonist treatment in bronchial asthma. Lancet 336: 1391–1396. Sears M R, Taylor D R.
(1994) The β2-agonist controversy: observations, explanations and relationship to asthma epidemiology. Drug
Safety 11: 259–283.
124 Dr Harry Morrow Brown FRCPEd (b. 1917) was Consultant Chest Physician in Derby from 1953 until his
retirement in 1982. He found sputum eosinophilia is linked with steroid responsiveness in 1958 (see note 126),
leading to major interest in allergic diseases and showed the effectiveness of beclomethasone dipropionate in
asthma in 1972 (see note 120). He founded the Midlands Asthma and Allergy Research Association in 1968, and
has continued clinical and aerobiological research to date.
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tuberculosis, for £1200 a year. Then after the TB was licked, I had to fight a battle
with colleagues and administrators for beds to treat other diseases of the chest. 
The conclusion of the MRC trial in 1956,125 that oral steroids were no better than
bronchodilators for asthma, was totally opposite to my own experience, but who was
I, working in a deprived clinic with no equipment, to say that the MRC were wrong?
However, I determined to conduct my own trial, so I scrounged a load of prednisolone
from Eric Morton at Boots and treated every apparent asthmatic I could find with it.
After three months I began to wonder if the MRC were right after all, as many cases
just didn’t improve, but those who did respond did so so obviously and so
dramatically, that it seemed as if I was treating a different disease. This was actually
true, because the responders had many eosinophils in the sputum and the others
didn’t. I seriously doubt if my 1958 paper describing this discovery126 would have been
accepted for publication today. There were no objective lung function tests, it was not
double-blind, the eosinophils were not counted by somebody else, and the statistics
were a simple table with an obvious result. However, ‘on-the-spot’ cytology enabled
me to select the steroid responders, ending up with very large numbers of steroid-
dependent, but very happy, asthmatics. 
Because I was sentencing these people to indefinite steroid dependency with all the
side-effects, I felt very unhappy. In fact, in the next few years I acquired more steroid-
dependent asthmatics than almost anybody. So I decided that the logical approach was
to try to identify the responsible allergens, if you could, in the hope that I could free
them from steroid dependence by avoidance or by specific immunotherapy, which is
a dirty word in this country. 
This decision also projected me into a completely different speciality, which has been
my obsession ever since, and unwittingly set the scene for the first trials of
beclomethasone, which was first tried out in Edinburgh, found ineffective, and in
bigger doses caused adrenal suppression, so that Allen & Hanburys nearly threw it
out. Fortunately, Wilfred Simpson, the medical director, had such faith in it because
of its skin activity, that he offered it to me for trial just before he left the company (in
fact two hours before), I have a letter from him to this day,127 and the late David
Harris, who took over from him, continued to support me with great enthusiasm. We
must also spare a thought for Sir David Jack, and his team, and how disappointing it
125 Medical Research Council, Subcommittee on Clinical Trials in Asthma. (1956) Controlled trial of effects of
cortisone acetate in chronic asthma. Lancet ii: 798–803. idem Controlled trial of effects of cortisone acetate in status
asthmaticus. ibid. ii: 803–806. Subcommittee members were: Professor R V Christie, Dr J G Scadding, Dr J T Boyd,
Dr W Brockbank, Dr E T Conybeare, Dr J J R Duthie, Dr A W Frankland, Dr R Kauntze, Dr M C S Kennedy, 
Dr H Nicholson, Professor G W Pickering, Professor F T G Prunty, Dr R S Bruce Pearson and Sir John Taylor.
126 Brown H M. (1958) Treatment of chronic asthma with prednisolone: significance of eosinophils in the sputum.
Lancet ii: 1245–1247.
127 Copies of the letters to Dr H Morrow Brown from W T Simpson, Head of Medical Services, Allen & Hanburys
Ltd, 16 July 1969 and from Dr D M Harris, Head of Medical Services, Allen & Hanburys Ltd, 9 February 1971,
are held, along with tapes, and other records received during the editorial process, in Archives and Manuscripts,
Wellcome Library, London.
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128 Wright B M, McKerrow C B. (1959) Maximum forced expiratory flow rate as a measure of ventilatory capacity
with a description of a new portable instrument for measuring it. British Medical Journal ii: 1041–1047. Wright 
B M. (1978) A miniature Wright peak-flow meter. ibid. ii: 1627–1628. For biographical details of Wright, see note 60.
129 Dr Harry Morrow Brown wrote: ‘Agreed by the Royal College of Physicians on 7 June 1999.’ Note on draft
transcript, 26 June 2001.
must have been to do all the research and find that the drug didn’t work in the clinic
when you expected it to work. The ability to select the allergic steroid responders,
especially children, because they are often completely reversible, was crucial to the
success of the first BDP trials. This time individual peak-flow meters128 produced
objective evidence that soon convinced Allen & Hanburys and other investigators –
many here today – that it was really useful. In February 1971, David Harris wrote, ‘I
have succeeded in obtaining a new lease of life for the steroid aerosol,’ and in October
1972 the Committee for Safety of Medicines became convinced of its safety and of its
ability to release many patients from steroid dependence. 
I don’t think these open trials would have been accepted today, but those were the
happy days when you could just get on with a trial without the ethics committees,
elaborate and restrictive protocols, double-blinding, statistics, and all the other
strictures that surround clinical trials today. I am sure many people will think of these
as halcyon days. But inhaled steroids, along with all the other drugs developed in
recent years, are at best only effective suppressants without serious side-effects, and in
my opinion life-long dependency on drugs for health is a most unsatisfactory
situation that we should not accept as normal. It makes sense, to me at least, to regard
drugs as a ‘chemical crutch’ to control the problem while attempts are made to find
the cause, yet this view is very rare indeed in the UK. If identified, the causative
allergies may be eliminated, or avoided, or if unavoidable, specific immunotherapy
introduced in an attempt to re-establish perfect adaptation. The recognition of allergic
disease as a speciality a year ago129 was only the first faltering step towards the time
when every district general hospital has an allergy department which treats and
investigates all sorts of allergies in all body systems. My fear is that by the time the
first trainees are ready for a consultant post, the hospital trusts will consider allergists
are unnecessary because the drugs are so effective and they want the money for
something else. Sue Arnold recently wrote in the Independent that when she saw her
doctor he always had his eyes focused on his computer, while he produced another
prescription. He never actually touched or even looked at her as doctors used to do,
once upon a time. I do hope this is not a glimpse of the NHS of the future.
Clark: I want to link Roger Altounyan with your very graphic tale, Harry [Morrow
Brown], on how you identified the steroid response in the unresponsive. I was going
to ask Jack [Howell] what happened to the Altounyan atropine test that was put
forward by Roger as a very good way of predicting steroid sensitivity before giving the
treatment? It has sort of disappeared. I used to love it. 
Howell: The Altounyan test is a test that I was emotionally attached to because it came
from Roger [Altounyan], but it took at least an hour to do. It also required an inquiring
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130 Professor Jack Howell wrote: ‘In addition to predicting responsiveness to corticosteroids, Roger used the test to
assess whether anti-inflammatory therapy was being maximally effective – if the response to atropine was
significantly less than the total response to both drugs given in this sequence, it was an indication to increase the
anti-inflammatory therapy. This is perhaps the most useful application of the test. He also showed that lack of
relative response to atropine correlated with the presence of sputum eosinophilia that disappeared as atropine
responsiveness appeared with effective corticosteroid therapy.’ Letter to Mrs Lois Reynolds, 6 July 2001.
attitude of mind, a model of what asthma is, or we believe it is, and I think most
clinicians today don’t have that time or that particular focus on asthma to bother with
a test that takes at least an hour to do. But if you do have the time, if you really are
trying to get an answer to a real question, then I still would commend this to people. 
Somebody asked what the test involved. You start off with a patient with a low FEV1
(forced expiratory volume in one second), atropine methonitrate is then administered
by nebulizer, and in 45 minutes to an hour, there may or may not be a slow response
to it. When that response has peaked at, say, three-quarters of an hour, isoprenaline is
then administered – yes, it had to be isoprenaline at that time – and then the patient
is measured for a further response. Now that means you will have a total
bronchodilator response, part of it due to the atropine and part of it due to the
subsequent isoprenaline, and the proportion of it due to isoprenaline represented the
steroid or cromoglycate-responsive component of that patient’s bronchial disease.130
Godfrey: I think you were basically saying that atropine is more effective in chronic
obstructive pulmonary disease [COPD] and the salbutamol more effective in asthma
or the equivalent.
Clark: But what was interesting was that if you started off with a patient who did not
respond, you treated them with steroids and then they did respond. The Altounyan
test changed to a poor response because having treated them effectively with
corticosteroids, they were not going to respond any more, and that is what the result
of the test would indicate when repeated. It’s a very good test.
Godfrey: I think probably we are going to be all right for time, but as somebody said,
you only have to mention Roger Altounyan’s name and everybody gets excited and
talks for two hours. Having got over that hurdle, and in a very enjoyable fashion, I
would like to ask Professor Warner to talk to us a little bit about the increasing
prevalence of asthma and the impact of allergy on asthma.
Warner: As I am not an epidemiologist, I am not going to talk about the epidemiology
of asthma, I will leave it to you to decide how much it has increased, merely to say that
all allergic diseases have increased. I wanted to reminisce a little bit about my evolving
interest in allergy as it relates to asthma and to carry on from what Harry Morrow Brown
had to say. I start with my mother because she had bad eczema as a child, developed
moderate to severe asthma in her teens and early adulthood, and also had hay fever. I can
remember her using one of those rubber bulb and glass atomizers and in the very early
1950s she had a course of desensitizing injections about the time that Bill Frankland was
doing his first double-blind placebo control trials of pollen immunotherapy. She
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benefited enormously from those injections and in fact didn’t have much asthma through
mid-adult life. I have to admit she is now in her seventies and taking inhaled steroids.
That was my first exposure to allergy in asthma. As an SHO in 1969, I can remember
treating asthmatic children in the Sheffield Children’s Hospital and one child comes very
much to mind, who spent all of his last year of his life in hospital because his asthma was
that bad. Growth stunted with continuous oral steroids, he went to school from the
hospital ward. He frequently required intravenous aminophylline131 and subcutaneous
injections with adrenaline just to keep him going. He eventually died in status
asthmaticus and I was left with the feeling that this wasn’t the way in which we should be
managing this disease. Then as a registrar in respiratory medicine in 1971, I actually took
over a desensitization clinic being run by Jerry Daley, a chest physician in Sheffield. In the
first year I did it with the senior registrar – lots of injections, witnessing healthy people
made unwell as a result of the injections. In 1972 we decided that as Intal was now
around, we would not give these injections. We would put all the patients on Intal and
close the allergy clinic with the support of the consultant. Having moved to Great
Ormond Street to work with Archie Norman later in 1972, I was then given the
opportunity to go into research, and what should it involve? An immunotherapy trial. I
want to read you a letter I found among my documents. It was written in December 1973
as part of the application to the Ethics Committee at Great Ormond Street for the trial
that I was to do. The letter was written by Edmund Hey132 and Archie Norman133 to the
Secretary of the research board and there’s one section here, in the first paragraph:
‘...conventional treatments for asthma, have improved symptomatic
management of this often chronically incapacitating and all too often fatal
condition, but no comparable advance has been made as yet in the
elimination or prevention of allergic bronchospasm.’
This provided the justification for conducting this immunotherapy trial, together
with bronchial allergic challenges to monitor effects on the early and late reactions,
which yielded rather interesting results.134 It actually took ten years for anybody else
131 Aminophylline is an injectable treatment for severe asthma attacks that do not respond to nebulized β2-
adrenoceptor stimulants. There is a narrow margin between a therapeutic and a toxic dose. For a review of drugs
used in the treatment of asthma, see Molinoff P B, Ruddon R W. (eds) (1996) Goodman and Gilman’s The
Pharmacological Basis of Therapeutics. Ninth edn. New York: McGraw-Hill, 659–682.
132 Dr Edmund Hey (b. 1934) trained as a respiratory physiologist in Oxford and worked for the MRC with
Kenneth Cross, Professor of Physiology at London Hospital Medical College; Geoffrey Dawes and Elsie
Widdowson for some years before moving to Newcastle to get a grounding in paediatrics in 1968. Professor John
Warner wrote: ‘Dr Edmund Hey was a consultant paediatrician working at the Hospital for Sick Children, Great
Ormond Street, London, who moved to continue his career in Newcastle. He is now retired. He is best known for
his seminal work on temperature control in the neonate. Dr Hey was an outstanding paediatric physiologist and
physician.’ Letter to Mrs Lois Reynolds, 16 May 2001. See also Christie D A, Tansey E M. (eds) (2001) Origins
of neonatal intensive care in the UK. Wellcome Witnesses to Twentieth Century Medicine, vol. 9. London: Wellcome
Trust Centre of the History of Medicine at UCL, 5, 10, 34.
133 For biographical details, see note 21.
134 Warner J O, Price J F, Southill J F, Hey E N. (1978) Controlled trial of hyposensitization to Dermatophagoides
pteronyssinus in children with asthma. Lancet ii: 912–915.
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to replicate our observations of the effect of immunotherapy on late bronchial
reactions,135 which worried me enormously because I thought that maybe my
observations were totally invalid. Roger Altounyan had heard my presentation about
the results, about the late reactions and the effect of immunotherapy, and he phoned
me up at Great Ormond Street sometime afterwards and said, ‘Look, are you still
doing the research?’ and I said, ‘No, I am back in my training programme. I am now
Senior Registrar, and have to go through the usual hoops.’ He said, ‘I feel this research
is terribly important and I am going to sort things out for you’. About two months
later he phoned back and said, ‘I have organized a position for you working in
Hamilton, Ontario, with Freddy Hargreave. How about going there to carry on with
your challenge work?’ I was, perhaps, stupid enough not to accept the offer at that
stage, but I have gravitated back to allergy very much more in recent years and have
become ever more convinced, like Harry [Morrow Brown], that there is more to
asthma than just drugs, and that there is a great deal more that we should be doing.
As Harry was speaking, I did notice some shufflings in the audience of people who
perhaps don’t quite hold the same view and perhaps still, like many people, look upon
allergy as being a side issue in asthma. I will quote something from a book that I have
found immensely valuable in my training, Respiratory Illness in Children, by Howard
Williams and Peter Phelan, the first authors of this book, first published in 1975.
These Melbourne paediatric chest physicians have been very instrumental in raising
the profile of the discipline, but in the chapter on asthma, Chapter 7, there are ten
pages on emotional aspects of asthma and only one page on immunological aspects.
On allergy skin tests they wrote: 
‘While such procedures are routine with most allergists, many physicians are
more cautious and skin testing is reserved for patients whose asthma is not
well controlled pharmacologically and in whom there is no serious
emotional disturbance.’136
Now I think it would be an interesting issue to discuss why there is this enormous
diversity of views from those who are total believers that allergy is the cause of
everything, to those who think it a concept totally inappropriate to think about in
relation to asthma.
Godfrey: Is that all? Very good, very succinct, but you haven’t told us anything about
the increased prevalence of asthma.
Warner: Well, you know it has increased. Who needs to say more? 
Godfrey: I am almost speechless, but I think that what I would say, personally, is I
have been convinced by a lot of very good studies that at least in children, ongoing
135 Van Bever H P, Stevens W J. (1989) Suppression of the late asthmatic reaction by hyposensitization in asthmatic
children allergic to house dust mite. Clinical and Experimental Allergy 19: 399–404.
136 Williams H E, Phelan P D. (1975) Respiratory Illness in Children. Oxford: Blackwell Scientific, 159–160.
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exposure to allergen is a major factor in the continuation of airways inflammation
which is the basis of bronchial hyper-reactivity which makes the patient susceptible to
all the various environmental influences, not just allergic challenges, that provoke his
asthma. And I have a very interesting recent experience with this, because as some of
you know I am currently on sabbatical, working with a company who devised the
hardware and software for online continuous monitoring of wheezing overnight.
Some studies are being carried out with Professor Boner’s children up in Misurina in
the Italian Alps,137 which is an institute for asthmatic children. I didn’t believe it when
I first heard about it, but I have now seen the children and seen the data, and you get
standard wheezy little asthmatics from Rome and wherever it might be, who go up to
an allergen-free environment up in the Alps there and a month later, they are doing
cross-country skiing. Now, as those of you here who are interested in exercise-induced
asthma know, cross-country skiing has to be about the worst possible sport for an
asthmatic for provoking the attacks, but I have seen the kids doing it, so there has to
be something – and they are off their medication, it’s not just that they are taking the
medication. The thing about the Misurina children is that they are symptom free, not
all of them of course, but a lot of them are symptom free, off their steroids and other
medication, and doing cross-country skiing. So you have to be very, very, very sceptical
not to be impressed with that kind of evidence. Going on from that, and I am not
going to let you get away with the increasing incidence of asthma. How can we relate
the increasing incidence to exposure to allergen, different exposure to allergen, reduced
incidence of infections and changes from TH1, to TH2-type, lymphocytes? What
about the immunizations from Southampton and your antenatal inception of asthma,
you people can’t get away with this, you must talk about it. This is great stuff.
Holgate: I would like to state that the rising trend of allergy is clearly established
worldwide. There is slightly more debate about the rising trends of asthma, because it
appears that this differs quite markedly country by country, which is not mapped by
the trends in allergy. One has to go to continents like Africa, or some of the more
remote islands, to see the morbid disparity between the prevalence of atopy and of
asthma. For example, when Richard Godfrey went out to The Gambia, in the early
1970s, the prevalence of atopy in schoolchildren there was in the order of 12 per
cent.138 In a recent survey conducted in the same population by Keith McAdam,
Director of the MRC Unit there, and his colleagues, the prevalence of atopy had
increased to 35 per cent.139 Yet in this population the current prevalence of asthma and
airways hyper-reactivity as a surrogate of a component of asthma, is only 0.3–1.0 per
137 Boner A L, Niero E, Antolini I, Valletta E A, Gaburro D. (1985) Pulmonary function and bronchial
hyperreactivity in asthmatic children with house dust mite allergy during prolonged stay in the Italian Alps
(Misurina, 1756 m). Annals of Allergy 54: 42–45.
138 Godfrey R C. (1975) Asthma and IgE levels in rural and urban communities of The Gambia. Clinical Allergy
5: 201–207.
139 Nyan O A, Walraven G E L, Banya W A S, Milligan P, van der Sande M, Ceesay S M, Del Prete G, McAdam
K P W J. (2001) Atopy, intestinal parasite infection and total serum IgE in rural and urban Gambian communities.
Clinical and Experimental Allergy 31 (in the press).
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cent. So here one sees a very large disparity. There are similar data coming out of
Ethiopia and Nigeria. So I think when one observes such a very different relationship
between atopy and asthma, then one needs to ask some serious questions about the
linear causation of asthma from atopy and allergen exposure. Thinking is beginning
to develop around the existence of two parallel pathways involving susceptibility genes
for atopy, the influence of which best fits with the ‘hygiene hypotheses’, and a separate
set of susceptibility genes expressed in the airways responsible for the structural
changes that occur and for sustaining the inflammation locally. For most of us who
see asthmatic patients over a lifetime, this disease is not a progressive disorder. In fact
it is a remarkable disorder that can vary so much from year to year. Harry Morrow
Brown, I think, can speak more about this than anyone. 
Warner: Stephen [Holgate] said much more eloquently what the state of the art is
with relation to allergy in asthma and I think most people would now agree. The
reason I made this comment about polarization of views is because I would like to
look at it from a historical perspective, because that’s what we are here for and it is very
interesting that at a time when there were no effective drugs available for asthma,
allergy was clearly the one approach that evolved from the beginning of the century
that seemed to have some impact, and immunotherapy and allergen avoidance were
regularly and routinely employed, not just in the first half of the twentieth century,
but even in previous centuries. Once effective drugs started to appear – almost a
British rather than a North American enterprise – allergy very rapidly faded into the
background. Obviously, the rapid onset of active pharmacotherapy eclipsed allergy in
Britain. However, in other countries pharmacotherapy has been very much slower to
evolve. North America is a fine example, where the allergist retained, as it were, a hold
on the scene for a great deal longer and maybe hasn’t faded quite so much into the
background in maintaining an interest in the allergic side of the condition.
Godfrey: I think we would be very remiss if we didn’t remember Jack Pepys140 in this
gathering, who really was the father of academic allergy wasn’t he? I was his houseman
at the Brompton and I remember at the time nobody believed a word he said, they
thought he was crazy, and of course he wasn’t and he really was the first person to get
going, doing academic allergy in proper scientific controlled experiments. He was
years before his time.
Silverman: I think it might be worth considering some explanations as to why there has
been this waxing and waning. I think, as John Warner has clearly pointed out, it relates
somehow to drug availability, but I think it might also be dependent on the quantity
of financial sponsorship for particular types of research. And we have been dominated
for the last 20 years by the large pharmaceutical firms pushing drugs, so that very few
140 Professor Jack Pepys FRCP FRCPath (1914–1996) came to the UK from South Africa in 1947 to sit for the
MRCP. He worked in clinical immunology at the Royal Brompton Hospital, London, setting up an allergy clinic
at the Institute of Diseases of the Chest, and in 1967 was appointed Professor and head of the first academic
Department of Clinical Immunology in the UK. The MRC funded his Clinical Immunology Research Group,
from 1960 to 1967 when financial responsibility was taken over by the Institute of Diseases of the Chest.
Childhood Asthma and Beyond
49
resources have been available for research in allergy in comparison with the amounts
that are spent on drug use. It may be that there has been a lot more profit to be made
out of pharmacological agents dealing with the consequences of allergic inflammation,
rather than in the potential for treating or preventing allergic inflammation, and I
wonder whether there is a commercial pressure that has actually diverted to some extent
the type of research that’s gone on over the last 25 years and possibly explains to some
extent the waxing and waning of allergy as a sort of favourite topic. 
Dr Donald Lane:141 Could I just come in to give a different slant on this point. There
is a very remarkable historical waxing and waning. I have just stopped working in the
Osler Chest Unit in Oxford. Now Osler viewed asthma quite differently to the way
we do. I am not saying he got it wrong, but he understood it differently. Asthma
appears in his textbook, in the section on neurology, under the heading ‘hysteria’. At
that time the whole emphasis on asthma was on the emotional and neurological
components, despite the fact that Henry Hyde Salter had described allergy absolutely
beautifully in the 1860s.142 By the early twentieth century allergy had gained
credibility and became a second mechanism for explaining the asthma phenomenon
and gradually the emotional component dropped out. It is, however, still present but,
because we have been given effective drugs for controlling the disease, we have stopped
asking why any individual has asthma. I think we need to start asking that question
again so that we can look into causation more carefully and tailor-make our treatment
for the individual. Undoubtedly some patients have a strong emotional or
psychological component; others have a strong allergic component. Yet others have
totally different mechanisms that half the time we don’t understand at all. I would like
to get back beyond the word ‘asthma’, which after all is only describing a syndrome,
to try to find out why individual patients are asthmatic.
Morrow Brown: If the present epidemic of asthma and allergies had happened 20 or
30 years ago, there would have been many more deaths, I am quite sure, because the
drugs weren’t there. We now have the drugs that are papering over the cracks with the
result that there is no interest in why all these children have got asthma at all. GPs
used to send so many patients for skin testing and investigation that there was over a
year’s waiting list, but that has all evaporated since they have learned how to use
inhaled steroids properly and are paid to have their own asthma clinics.143 I would like
to propose that we pay more attention to childhood asthma in particular, because if
you can do something for the children, perhaps they will have a chance to grow up
into asthma-free adults. My experience with effective acaricides, for example, showed
that there is a minority of younger patients who, if they are in a mite-free atmosphere
or a mite-free environment for long enough, will cease to respond to challenges
presented by dusty environments that have not been cleared of mites. Just like the
141 Dr Donald John Lane (b. 1935) was Consultant Chest Physician at the Osler Chest Unit, Churchill Hospital,
Headington, Oxford, from 1971 to 2000. He has been Vice-President of the National Asthma Campaign since 1993.
142 See note 10. 
143 See page 54.
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children in the Alpine schools, some will lose their sensitivity to mites with long-term
avoidance so that they do not relapse on returning to Rome. 
Finally, I would like to say that specific immunotherapy has got a bad name, and its
premature and misguided abandonment really gave asthma over totally to the drug
manufacturers. But if we use immunotherapy properly it works. My approach was
that they [patients] should not receive immunotherapy unless they had a positive
bronchial provocation test, so that at the end of the course a negative bronchial
provocation test could show that they had achieved immunity. If not, further
immunotherapy could be given until the provocation test became negative. That sort
of objective approach is what’s been missing in the past.
Godfrey: I think the Warners, Jill and John, would say what you really need to do is
to prevent the mother getting allergic and giving TH2 lymphocytes to her fetus. Like
Bray says, ‘Don’t marry allergics’. Back to that. 
Clark: I will be quick. We were just talking about historic anomalies, or possible
historical anomalies, and I will avoid injecting an acerbic note into this, to try to keep
it all friendly. One of the interesting distinctions, looking internationally, is the failure
of allergy as a speciality in the UK and that is a very big issue that requires debate now.
I personally wholly subscribe to the point of view that Harry [Morrow Brown] put
forward about his patients who became steroid-dependent asthmatics. There must be
something better than having patients dependent on medication. If you and the
patient can avoid the cause for the medication, the patient is much better off. But
whether you need a separate speciality is a very big issue and I feel that this is
something that is about to be debated again. I personally don’t think you do, but there
are many people who think the opposite. I think we should just note the historical
anomaly in this country, which is relatively unusual in not having a clinical speciality
of allergy, and it may be our troubles are because we haven’t had the speciality.
However, I think there are other conclusions you can draw.
Brewis: I was going to bring up the dulling effect of effective treatment on curiosity,
and I was going to lead on to the effect on one’s life as a clinician. Much of what we
have been talking about so far is in the literature and I wondered whether you would
like to tap into the experience that people have had in respiratory medicine, treating
asthma in childhood and adult life, which doesn’t appear in the literature. 
I have done 30 years, just finished. In the early years my clinics were dominated in the
asthma context by what I used to characterize as a steroid confessional. People came
to confess how bad they had been, allowing themselves to have just a little bit more
prednisolone. On the whole people undertreated themselves, they were so fearful of
side-effects, and you had to make them feel better about this. Then along came steroid
aerosols, and then there was a period when I had a rush of people with hypoadrenal
symptoms, although not enough to write up. There was very little written up, apart
from a lot of irrelevant stuff about giving adrenocorticotropic hormone (ACTH) and
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weaning people off.144 But people used to come in as emergencies, collapsed with
apparent flu or hypotension. People were investigated for diarrhoea of mysterious
cause, had headaches and felt gravely unwell. They were hypoadrenal. They had their
steroid aerosol, keeping their asthma absolutely fine; nobody thought that they were
short of steroid, but they were. This gradually faded out during the later 1970s. After
the 1970s asthma gradually became a GP disease and in hospital practice you were
only really sent people who had terrible, intractable disease. Also, you no longer saw
so much missed asthma. I used to see at the beginning of this 30-year period a
blindness on the part of many GPs to asthma. Anybody that coughed had chronic
obstructive pulmonary disease (COPD), and when I went to Newcastle 30 years ago
I turned over huge amounts of apparent COPD and gave them steroid trials to show
that some had asthma. Gradually practitioners and practices would learn to recognize
these and you would realize that you wouldn’t get any more cases from that particular
practice. They had twigged. So there was quite a big change. 
I would suggest almost three phases to those 30 years of experience as a respiratory
consultant, and a lot of people will recognize that there must be many anecdotes,
many features of life in respiratory medicine dealing with asthma that you could get
from your audience here, which are not actually being published and I wondered
whether you would like to try.
Gregg: Can I reinforce one or two points that have been made, particularly by Donald
Lane. First of all, I think we should be rather more careful with our use of terms. We
talk about asthma as if it were one disease, and yet everybody with clinical experience
knows that it is shot through with contradictions and paradoxes. Hence it is most
unwise to generalize about asthma. Also, when talking about allergy, are we really
talking about atopy? Most of us have been, I think, this afternoon. But after all where
you find no evidence of atopy at all in some of the occupational asthmas, particularly
with TDI (toluene diisocyanate), there is no evidence of atopy that I know of and yet
even after removal from exposure some patients continue having asthma. So
presumably they are allergic. 
To go back to Roger Altounyan, who I am sure would have liked us to derive as much
from his experience as we can. I think that he was generally regarded as having atopic
asthma. Certainly in childhood he did know from experience that eating chocolate
had appalling effects. Yet he never had asthma as a child and he was passed fit for the
Air Force as a fighter pilot during the Second World War, clearly indicating that he
must then have been a very fit man. I always understood that was where he got the
idea of the propeller of the Spinhaler. It was only towards the end of his medical
studentship did he suddenly develop asthma that persisted for the rest of his life. He
challenged himself repeatedly by inhaling substances that provoked acute asthma
144 Carey R A, Harvey A M, Howard J E, Winkenwerder W L. (1950) The effect of adrenocorticotropic
hormone (ACTH) and cortisone on the course of chronic bronchial asthma. Bulletin of the Johns Hopkins
Hospital 87: 387–414.
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(thereby discovering Intal that protected him against their effects) and this would
seem to suggest that the attacks were atopic in nature. I don’t know what his skin tests
were, I always meant to ask him and I never did. He used to smoke quite a lot too, a
pipe, and the word was that it was a nonspecific effect and the Intal in him anyway
was working to prevent what is usually only done in atopic people. We don’t know.
His chronic asthma may have been due to a different mechanism.
Dr George Russell:145 I want to say a few things about the changing scene in the asthma
clinic that Alistair Brewis referred to. I think it is fair to state that when I came back from
the States in 1965, the asthma clinic in Aberdeen, started by Professor Ross Mitchell,
was very heavily allergy biased and every patient who came had skin testing done, and
every patient had advice on allergy. Then of course in the late 1960s and early 1970s, we
got all the new drugs. We also at the same time were inundated with large numbers of
patients and we hadn’t the time to skin-test them all and work them up in the way that
we used to do. I think one of the reasons why allergy has gone out is because it is so
labour intensive. It takes time, it takes people, it can’t be done by machines, and many
clinicians are insecure about it. It is easier and takes much less time to manage patients
pharmacologically. Now, what I have seen since then is a gradual change towards getting
more and more difficult asthmatic patients who aren’t responding outside hospital.
Furthermore, in the last four or five years we have also seen an inundation of people who
are not asthmatics, but who have been labeled asthmatics, because of all the publicity
about asthma and all the enthusiasm for things like coughing asthma. Most of these
patients don’t respond to antiasthma therapy. They come to us and are very upset when
we have to amputate the diagnosis of asthma from them and tell them that what they
have is whooping cough, habit cough or whatever. [From the floor: Postnasal drip.] 
Also I would just like to make a little retrospective comment on the introduction of
Ventolin. I was extremely interested to hear that when Ventolin was introduced, what
was being looked for was a long-acting isoprenaline, because my recollection of its
initial use was that its prolonged action was indeed its scoring point.146 Safety wasn’t a
major issue. The advance on isoprenaline was the fact that it lasted three or four hours
instead of five to ten minutes, and children could get it first thing in the morning,
were well until lunchtime when they could get more. Indeed it was often used as a sort
of prophylactic much in the way that salmeterol is used nowdays. 
Dr Jill Warner:147 Listening to George [Russell] speak made me want to thank the
people running those allergy clinics in 1965, because a lot of the results that have
145 Dr George Russell FRCP (b. 1936) was a consultant paediatrician at the Royal Aberdeen Children’s Hospital
from 1969 until 1996 when he retired to join the staff of Aberdeen University as Reader in Child Health. He has
contributed various papers on the increasing prevalence of childhood asthma, and on its treatment.
146 Riding W D, Dinda P, Chatterjee S S. (1970) The bronchodilator and cardiac effects of five pressure-packed
aerosols in asthma. British Journal of Diseases of the Chest 64: 37–45. Kamburoff P L, Prime F J. (1970) Oral and
inhaled salbutamol as a bronchodilator. ibid.: 46–54. 
147 Dr Jill Warner (b. 1962) is Senior Lecturer in Allergy and Immunology and Coordinator of the MSc training
programme in allergy at the University of Southampton.
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come from those large cohorts have been the basis for much of the work that we are
now doing. You mentioned the antenatal work. A lot of the support for that comes
from the observation that you see an increased risk of mothers with asthma going on
to have children with asthma. The people who made those observations have given us
the opportunity to go on now and look at more of those causal factors, which must
be occurring during pregnancy. 
Godfrey: Would Mrs Greta Barnes like to come on and set the ball rolling, because
we want to move a little bit to our next topic, the impact of, well, the role of, support
organizations that have evolved and how that’s affected the asthma scene over the
years. I think last and by no means least we are going to talk a little bit about
phenotypes of asthma and that really comes back to George Russell’s point about the
coughing asthmatics or nonasthmatics.
Mrs Greta Barnes:148 Maybe it’s important to say to those of you who don’t know me,
that I am not a doctor. I am a nurse by background, and in 1983 I was just finishing
a role with the Medical Research Council, when our GP, Dr Robert Pearson, turned
to me and said, ‘You have looked at diabetes, you have looked at hypertension, I think
we have got a major problem with asthma in the practice. We know it’s increasing and
patients are not getting a good deal; why don’t you spend some time researching,
looking at the role of the nurse in asthma?’ So I did this for a year and we found that
by utilizing nursing skills, we were able to reduce the acute nebulizer use, but
inevitably what we did was to increase the inhaled corticosteroid use, which won’t
surprise any of you. Now I have to admit that I have got two heroes, one of them
knows who he is because he’s sitting over there, Tim Clark, but the other one I have
never met before and it’s this gentleman [Simon Godfrey], because I learnt all the
asthma that I could possibly learn from the ‘green book’,149 and you went to bed with
me night after night. [From the floor: It gave me great pleasure.] We also visited Ian
Gregg who was incredibly helpful, we went round various hospitals and I was a real
nuisance, because I wanted to know what was going on, and the one thing that struck
me at that time was we were giving messages that were too complicated for the
patients to understand. Patients needed to have simple messages. The major
requirement was that we needed to make people understand that prevention was
possible, and that our goal should be having patients without symptoms. 
One day in 1986 I happened to see that a tiny property opposite our medical centre
was for sale. I thought that it would be ideal to use as a training centre for nurses and
doctors. I am not, as some of you will know, frightened of the medical profession and
I thought it would be a good idea if we could just set up a training centre for diabetes,
asthma and hypertension. Three chronic disorders, wonderful, that’s the way general
practice should go! Perhaps historically this is quite important because we tried to get
148 Greta Barnes MBE (b. 1940) is the founder and Director of the National Asthma and Respiratory Training
Centre in Warwick, which was established in 1986.
149 Clark T J H, Godfrey S. (eds) (1977) Asthma. London: Chapman and Hall. The second edition in 1983 was green.
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funding for setting up a training centre for the three conditions. We went to industry
and we went to the charities and we were able to attract a very small amount of
funding from what is now the National Asthma Campaign and from Allen &
Hanburys. We were unable to attract funding for the other two disorders, and I
suspect that things might have been very different if we had actually managed to do
so. The training centre was set up with charitable status and we ran a three-day course
for nurses with their GPs coming on the last day. The reason the GP was invited was
to promote teamwork and it seemed what we mustn’t do was to antagonize doctors.
We needed to show we were working together, we were not trying to work separately.
Well by 1990, several things had happened. One was that the British Thoracic Society
(BTS) Guidelines were introduced,150 secondly, there was a new GP contract that
meant that GPs could get money for running asthma clinics. GPs quite like money
and so this made a huge difference. And thirdly, we had introduced the Diploma in
Asthma Care programme, which was six months’ distance learning, including face-to-
face teaching as well as a written and practical examination. I do wonder sometimes
whether introduction of the guidelines resulting in the increased use of inhaled
steroids, the new GP contract,151 or possibly the fact that we were working very hard
on introducing nurse-run asthma clinics, had an effect on the reduced death rate. I
don’t think we are ever going to know which it was, but it is likely to have been a
combination of all of them. By 1992, the UK had the chronic disease management
programme in place when focused on asthma and diabetes. So this meant that we were
hugely in demand, because GPs wanted to run asthma clinics. By 1993 the training
centre had introduced 12 different courses which ranged from essential skills
workshops to diploma-level courses,152 including allergy, where we worked very closely
with the experts, including Steve Holgate. We also introduced a respiratory Master’s
level course in conjunction with Sean Hilton at St George’s Medical School. Currently
we have trained approximately 20 000 health professionals. The number has increased
internationally as well as in the UK. You may say, ‘How have you achieved this?’ The
answer is that we have a very large national training network. We have 60 trainers in
this country, as well as in Canada, America, Norway, Denmark and several other
countries besides. The trainers are practitioners, whom we have put through a special
programme to enable them to train others effectively. We also have 250 educators in
the UK as well as regional training centres. So, really, that’s the way that has been
achieved. It has been through the tremendous support from the nursing profession,
but in addition, and I suspect the chief reason, has been the support and
150 British Thoracic Society et al. (1990) Guidelines for management of asthma in adults: I: Chronic persistent
asthma. British Medical Journal 301: 651–653. idem Guidelines for management of asthma in adults: II: Acute
severe asthma. ibid.: 797–800. Revised and extended to include asthma in childhood in idem (1993) Guidelines
on the management of asthma. Thorax 48 (2 Suppl.): S1–S24.
151 Department of Health and the Welsh Office. (1989) General Practice in the National Health Service: A new
contract. The Government’s detailed proposals for changes to the GP’s terms of service and remuneration system. London:
HMSO.
152 Barnes G. (1998) The nurse’s role in asthma management. Seminars in Respiratory and Critical Care
Management 19: 593–601.
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encouragement from the medical profession. Our trustees have been superb, two of
whom are here today, as well as our medical adviser, and people like Tim [Clark] who
opened our fourth and latest headquarters in Warwick. 
Godfrey: Thank you very much and a great contribution it is. I beg your pardon, Dr
Lane, would you like to add a few words along these lines? The organization of education.
Lane: I have worked closely with Greta [Barnes] in the training centre as a trustee, but
perhaps I could put a historical perspective on voluntary organizations for asthma.
The modern medical charities started in the 1890s. It’s interesting that the first one,
perhaps not surprisingly, was for tuberculosis, but following that, very quickly, were
the two cancer charities that still remain.153 And in fact the next one was for asthma,
but that was not until 1927, when the Earl of Limerick, concerned about the lack of
understanding of this disease, formed the Asthma Research Council. That
organization funded research through the next 40 or 50 years at a fairly modest level,
so that by the time of the introduction of Intal and the asthma deaths epidemic it was
still only putting about £300 000 to £400 000 per annum into asthma research. Then,
stimulated by the upsurge of asthma deaths, a lady called Helen Wilde, whose own
daughter had died of asthma sometime earlier, joined the Asthma Research Council
and set up the Friends of the Asthma Research Council, which was there to aid fund-
raising for research. However, you can’t bring together people interested in fund-
raising for asthma, without their starting to inquire about their asthma, because a
significant proportion of the fund-raisers were asthmatics themselves. So towards the
end of the 1970s a group of us looked at other charities that had a specific
patient-support function in order to decide whether we should have one for asthma.
That decision was in the affirmative, and so the Asthma Society came into being in
1980. The medical background that was important, and noted at that time, was that
we had two effective measures in the therapy of asthma: good controlling drugs, the
steroids, and cromoglycate, as well as good relief medications. That left the issues of
the delivery devices and patient education. Patients weren’t taught how to use the
devices properly and didn’t really understand the difference between steroids and
bronchodilators. And that’s why the Asthma Society started with an educational
programme involving patient groups,154 the branches that brought asthmatics together
for support. It was very successful. The Asthma Society and the Research Council were
run from the same office for a decade, but for organizational reasons it was obviously
best that they came together, which they did in 1990. The National Asthma
Campaign was the result, a charity campaigning on behalf of asthmatics with
Government and public bodies. It has introduced a very popular telephone helpline.
The balance is shifting now from patient support groups to the service that is available
through general practice asthma clinics staffed by the sort of nurses that Greta
(Barnes) has trained. The National Asthma Campaign continues to fund research,
153 The Cancer Research Campaign and the Imperial Cancer Research Fund.
154 For another example of patient groups, see Tansey E M, Christie D A. (eds) (1999) Haemophilia: Recent history
of clinical management. Wellcome Witnesses to Twentieth Century Medicine, vol. 4. London: The Wellcome Trust.
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which now instead of being £300 000 to £400 000, is now £3 to £4 million. Quite a
success story.
Godfrey: You said that it was started by Limerick. 
Lane: The Earl of. Not the one who invented the rhyme.
Godfrey: In that case, I am afraid I am irrepressible. 
There was a young man with a wheeze, 
Whose doc said asthma’s a breeze, 
Just take a puff of that steroidal stuff,
And you will be able to breathe with ease.
Dr McCarthy, please carry on in the same vein. You don’t have to make up a limerick
on the spot. 
McCarthy:155 I do have a limerick but I had better not repeat it. For many years I
was a GP in Suffolk and, like others of my contemporaries such as Mac Cochrane,
was inspired by the enthusiasm and example of Tim Clark in developing an interest
in asthma. I went into practice in the late 1970s and at that time it became clear
fairly quickly that asthma in primary care was dramatically undiagnosed and also
under-treated. There was significant morbidity and, from publications that had
come out in the late 1970s and early 1980s, also a mortality that was unacceptable
because of the preventable causes that have been pointed out. There was an also an
increase in prevalence and I suppose, if we talked about children in particular, there
were probably about something like 15 to 20 per cent of children with asthma who
were receiving some kind of appropriate treatment. I had a major interest in
children as I trained in paediatrics and anaesthetics, and I think the big change in
primary care came about when it was recognized that asthma was a disease of
inflammation as well as of bronchial constriction. The use of cromoglycate first and
then of inhaled steroids made a significant difference. Steroids were used mostly in
adults and, I think, with children there was probably the difficulty of getting the
drug into them. The development of the large-volume spacers really made a
considerable impact on the management of younger children with asthma and
enabled us to deliver both bronchodilators and prophylactic medication such as
steroids to these children. 
I suppose as a result of my interest in anaesthetics, I was very keen to get the drugs
into the small babies and initially used an anaesthetic mask that had become attached
to me when I left anaesthetics. I then attached this to a spacer and saw that if I could
deliver a drug into babies in this way, we might be able to treat smaller children. Over
the course of three years, I worked, cutting and pasting, and using sellotape, to
develop some kind of a mask and thought that this was kind of relatively innovative,
155 For biographical details, see note 72.
Childhood Asthma and Beyond
57
until I saw in arriving here that ten years earlier a doctor in Canada, a Dr Freigang,156
had done it all before and had developed his own large-volume spacer and his own
mask. But it did mean that we could now deliver medicines to children of all ages,
providing that we were convinced that they had a diagnosis of asthma. And I do say
that ‘providing we were convinced’, because I think we have come to rely a little over
much on drugs and have come to apply the diagnosis possibly in small children
inappropriately.
It would not be possible to talk of the work of looking after asthma in primary care,
without giving a further tribute to Greta Barnes, because the impact of nurses who are
trained in asthma care and primary care has probably made the biggest single impact,
even more than most drugs. It enables nurses, who are better at communicating with
patients than doctors, to sit down, talk to patients, listen to them, find out what was
wrong, try to develop with them an understanding of how the disease should be
managed, and then teach them how to do it. In the late 1980s, enthusiasts, two of whom
are here today, and again I think tribute needs to be paid to Mark Levy157 and Sean
Hilton,158 who had the foresight to realize that if the care of asthma could be promoted
among doctors in primary care, that would also have a major impact. They founded the
‘GPs in Asthma Group’159 and again that group has continued to work for the last 11
years, promoting the care of asthma in primary care. As Greta said, the initiation of
government-funded asthma clinics had a major impact, although that funding is now
largely withdrawn, which makes it difficult to initiate new asthma clinics.
The level of diagnosis is now good, but I do think we are in danger, as I have said, of
applying the diagnosis inappropriately to young children. Fernando Martinez and his
group in Tucson have pointed out that coughs and wheezes may not be asthma.160
156 Dr B Freigang wrote: ‘The prototype of an inhalation device was constructed from a plastic vinegar bottle with
a face mask glued to one end and on the other end, a one-way valve which replaced the MDI [metered dose
inhaler] after actuation. As soon as the glue was dry the chamber was tried out on Darren [a 12-month-old boy],
who was discharged home with instructions to continue on beclomethasone indefinitely. Darren’s subsequent
hospital admissions were few and far between. The use of “A new inhalation device” was published in the Canadian
Medical Association Journal in 1977 [Freigang B. (1977) New method of beclomethasone aerosol administration
to children under 4 years of age. Canadian Medical Association Journal 117: 1308–1309]. I soon tired of gluing my
fingers together...and the following year a plastics company manufactured the device for my patients. A trade mark
was secured as the Aerosol Inhalation Device for Asthmatic Children (AIDAC).’ Letter to Dr Chris O’Callaghan,
5 September 1997. This letter contains further details of the spacer development and it will be deposited, along
with copies of all additional correspondence received during the editorial process, with the records of this meeting
in Archives and Manuscripts, Wellcome Library, London.
157 For biographical details, see note 180.
158 Professor Sean Hilton FRCGP is Professor of General Practice and Primary Care at St George’s Hospital
Medical School, London, and Head of Department.
159 Levy M. (1993) The General Practitioners in Asthma Group. Primary Health Care Management 3: 10. Since its
formation in 1987 its scope has broadened to become the General Practice Airways Group (GPIAG). Its
membership includes nearly 1000 general practitioners with an interest in respiratory diseases common in 
primary care with primary care nurses and other allied healthcare professionals as associate members. 
See www.gpiag-asthma.org/ (visited 10 July 2001).
160 Wright A L, Holberg C J, Morgan W J, Taussig L M, Halonen M, Martinez F D. (1996) Recurrent cough in
childhood and its relation to asthma. American Journal of Respiratory and Critical Care Medicine 153: 1259–1265.
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George Russell has also made the point.161 I would very much echo Mike Silverman’s
comments in terms of ‘Are we avoiding what is causing our patients’ asthma?’ I think
with drugs freely available and encouraged by the industry, we should follow a
paradigm in managing our patients, the first element of which should be avoidance. I
think if we have not sought to avoid all the trigger factors that are impacting upon our
children’s asthma, we do them a disservice. And it is not enough to ask the parents if
they smoke in the garden, because in Liverpool all parents smoke in the garden, and
a study was published recently showing that cotinine levels in children whose parents
smoke in the garden were exactly the same as those of parents who smoke in the
house.162 The work of nurses is critical in helping understand patients’ problems taking
their therapy. It isn’t enough to educate, and I think only by taking into account what
motivates the patient into taking their therapy, will we truly understand how to help
them to manage their disease. We forget sometimes that we are making them ‘able’ by
giving them effective treatments, but we are also reminding them of their disability by
giving them treatment that they have to take on a regular basis. Device selection is
critical and the British Thoracic Society (BTS) guidelines163 in 1990 said that the
commonest cause of failure in treatment in small children was in correct device
selection. Device selection, I believe, does need to be tailored to patients; we do need
to take them into account. The guidelines have made a major impact and drawing
together wider groups into guideline formation, I think, and making them more
evidence based will lead to their more successful use. One thing that struck me while
I was looking at the evidence for this, for managing asthma, is that studies have been
carried out on morbidity, showing that patients wake at night, in unacceptably large
numbers, they miss work, they miss school, they can’t do their exercise, but the figures
haven’t changed from 1990. So something is going wrong and I feel that in spite of all
our therapies, we are still not communicating sufficiently with patients and
understanding their needs, and how they wish to manage their disease. I think the way
forward is not just avoidance but understanding the patient better.
Godfrey: Thank you very much. Very good. I think if the data from the Southampton
study, the study and analysis of mortality trends, are correct, it shows that in the 1990s
that asthma mortality is not rising, or may even be falling at 6 per cent a year, while
the incidence of asthma is still apparently going up, which really implies that
something is being done right. The one big thing that’s happened is the education of
doctors, nurses, practices and everything else, that’s the new thing of the 1990s isn’t
it? I mean as far as steroids are concerned, you can change the molecule a little bit this
way or that, or change the device, but that’s not really such a big thing.
Clark: This is really an excuse for me to pay tribute to Greta Barnes, but she knows
my feelings, so I won’t pursue that. If I could just use this opportunity to mention a
161 Russell G. (1996) Childhood asthma: how best to manage the disease. Clinical Immunotherapeutics 5: 96–114.
162 Bahceciler N N, Barlan I B, Nuhoglu Y, Basaran M M. (1999) Parental smoking behaviour and the urinary
cotinine levels of asthmatic children. Journal of Asthma 36: 171–175.
163 See note 150.
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little bit about guidelines164 in this historic review, as I, along with Steve [Holgate]
and Martyn Partridge and others, have been involved with them, in their relatively
brief lifespan.
One can argue until the cows come home as to when guidelines first appeared, and
how you define what is a guideline, but they really began to appear about ten or 12
years ago. They first gained international momentum at a meeting convened by
someone whom I would also like to pay tribute to, Freddy Hargreave, who convened
the meeting in Canada with good old Jerry Dolovich and Mike Newhouse.165 This was
conceived as a way of trying to gather together experts from all over the world, because
of the disparities in treatment that were perceived throughout the world, to see how
best one could control asthma. I think ‘control’ was a very important word, although
one can argue about whether it’s the right word. In other words, there was a step
change in therapeutic strategy from treating asthma symptoms, to preventing them,
and to finding some way of controlling them to improve the quality of lives of
individuals. Over the last decade guidelines have just blossomed and you can hardly
turn without a new set of guidelines and revisions of guidelines. I would just like to
make one caveat touched on by what Paul [McCarthy] was saying. There was a recent
survey of asthma in the USA that revealed again the very high morbidity that still
exists there.166 The same applies here, the morbidity hasn’t changed very much, but the
one question that I really enjoyed most in the American survey, was a question relating
to the patients’ understanding of their treatment. The previous questions had
established that education was very important to recognize and understand,
‘preventer’ treatment and ‘reliever’ treatment, or whatever the Americans call those
treatments. And one of the questions towards the end [of the article] was ‘now could
you identify which is your preventive treatment?’ or controller treatment, or whatever
it was, and the top drug identified by patients was inhaled β-agonist, and I think that
is telling us a lot. 
We have grossly failed with guidelines, as we may all think we know how to treat
asthma and have consensus, but we have a long way to go in conveying that where it
really matters and enabling the goal of self-management to really work. In that respect
Greta’s activities and the work that she is doing, I think, are much more important
than what a lot of other people are doing.
Godfrey: I personally think the guidelines are important for explaining to doctors and
other people working with asthma, that there is a step-wise approach to asthma
management. Not all asthma is the same and some patients need more treatment and
164 For the original guidelines, see note 150. For further revisions, see note 93.
165 Dolovich J, Hargreave F E, Wilson W M, Greenbaum J, Powles A C P, Newhouse M T. (1982) Control of
Asthma. Canadian Medical Association Journal 126: 613–618.
166 For details of the survey, see www.asthmainamerica.com/ (visited 5 July 2001). See also Rabe K F, Vermeire 
P A, Soriano J B, Maier W C. (2000) Clinical management of asthma in 1999: the Asthma Insights and Reality
in Europe (AIRE) study. European Respiratory Journal 16: 802–807.
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if you need more it should be given in a logical fashion, rather than having a whole
bundle of drugs dumped on the desk at the same time, used higgledy-piggledy as they
are in many places. Much less here than they are across the Atlantic maybe. I would
like to see some evidence-based medicine that the guidelines really do something.
Personally I happen to feel that the American version, Global Initiative for Asthma
(GINA) guidelines are completely impractical, because they assume that the patient is
receiving no treatment whatever when he comes to see you, so then you can decide
how bad he is and give him the treatment, which is ridiculous. The BTS guidelines
don’t assume that. They assume first of all you treat him and then you find out how
bad he is by saying what step he is on, which is nice, but I mean it doesn’t actually
really help you. What we really need is something that gives an unbiased estimate of
severity. I was joking around with Mike Silverman yesterday, saying that I would like
the blood rhubarb test, by which the blood rhubarb would tell me how bad the
asthmatic is, what treatment he needs, and follow him by following the levels of blood
rhubarb. This would be fine, but I don’t think we have it.
Warner: There is actually an evidence base on guidelines, which suggests that national
and international guidelines are totally ineffective.167
Godfrey: Well, I was trying to be polite.
Warner: The guidelines which work are those that are developed locally with patients,
and that are practical and reinforced in the clinic setting, rather than being an ivory
tower-generated edict. But I just wanted to come back to what Paul [McCarthy] was
saying. I neglected to say anything about epidemiology when I got up to speak,
because I didn’t feel that was my position to do so, but we recently have done a study
to look at how many wheezing children are diagnosed as having asthma and
consequently receive appropriate treatment for asthma. You can see over the last 20
years that a progressively higher percentage of recurrently wheezy children are now
labeled asthmatic and a progressively higher percentage are receiving appropriate
treatment for asthma. Those children left as wheezers, that are not receiving asthma
treatment and don’t have an asthma label, in general have very infrequent, very mild
disease. Therefore there probably is no more need to drive people to make more and
more diagnoses of asthma in that category of patients, because they are very mild
anyway. The pressure that is being put on us to do that is creating a problem, and as
other people have said, many patients are being referred as uncontrolled asthmatics,
on the basis of a lot of asthma treatment, but they haven’t got asthma at all. 
Godfrey: I think that is a marvellous introduction for Mike Silverman to talk about
what is and what isn’t asthma.
Silverman: As an aside, I would just like to congratulate everybody for not trying to
define asthma – well done. We’ve been through this repeatedly for many years.
167 Woolf S H, Grol R, Hutchinson A, Eccles M, Grimshaw J. (1999) Clinical guidelines: potential benefits,
limitations, and harms of clinical guidelines. British Medical Journal 318: 527–530.
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I think there is an interesting story here, because attitudes to asthma and wheezing in
paediatrics have changed noticeably over the last 30 or 40 years, and it’s more than
simply terminology. The story relates to wheezing diseases in childhood, because
attitudes have changed considerably. In the 1960s there was a distinction, and the
Aberdeen cohort that has been referred to is the embodiment of this168 – a distinction
between wheezy bronchitis and asthma in Aberdeen, not just in pre-school children.
There was an acceptance that amongst the wheezing disorders of childhood, there
were different types of disease. There was something called wheezy bronchitis, which
was generally wheezing and coughing (a wet cough) associated with acute infections,
and there was asthma, which we all recognize as being generally an atopic disorder.
But then in the 1970s (and I think this is interesting and more than a coincidence),
with the development of effective therapy we were urged to call all wheezing asthma,
not to split, but to lump the whole lot together. And that is probably because there
was effective therapy for the first time and it was realized that using antibiotics and
other therapies for wheezy bronchitics wasn’t the appropriate thing to do. Therefore
we were urged to make the diagnosis of asthma more actively, and the diagnosis was
accepted because there was a form of therapy and treatment with effective drugs.
There was also, and there has been increasingly, an increase in the promotion of drugs
and awareness of asthma and diagnosis of asthma by all organizations with an interest,
whether commercial or noncommercial. And whether by coincidence or not, the
epidemic of asthma really started in the late 1960s and 1970s and it became obvious
that there was an increasing amount of it. So in the 1970s it became unfashionable to
think of different subclasses of asthma and we all had to call everything that wheezed
in childhood, asthma, and that I think was a mistake. But it may have been an
inevitable consequence of the new drugs. We have talked a lot this afternoon about
how drug development has influenced the way in which we have all behaved and
practised medicine, and I think this is another example. 
In the 1980s there was an increase in recognition that what had become known as
phenotypes of asthma, different types of wheezing disorders, were detectable in the
population of wheezing children. And I will say as an aside that I think this is now
feeding through into adult practice (and it is one of a number of examples I could give
you of attitudes in paediatrics that have begun to have an effect on chest physicians, too),
and allow them to begin to think of asthma phenotypes or different varieties of asthma
in adults. Obviously there are some leaders in this field like Donald Lane here, who have
always been aware that there were different forms of asthma, as he hinted earlier, but
among the majority that hasn’t been the case. Evidence accumulated in the 1980s with
epidemiological studies,169 with studies looking at the outcome of wheezy bronchitis, as
opposed to atopic asthma and I think with the important publication by Nicola Wilson
who isn’t here today, in 1989, which raised the question: ‘Should we really be thinking
168 Dawson B, Illsley R, Horobin G, Mitchell R. (1969) A survey of childhood asthma in Aberdeen. Lancet i: 827–830.
169 See, for example, Sporik R, Holgate S T, Cogswell J J. (1991) Natural history of asthma in childhood – a birth
cohort study. Archives of Disease in Childhood 66: 1050–1053.
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about a separate disorder and not lumping this particular variety of wheeze together with
the rest of asthma?’170 In the 1990s there was increasing awareness of the benefits of
splitting wheezing disorders in childhood into subsets to begin to look, as Donald [Lane]
said earlier, at the possibility that they have different mechanisms requiring different
forms of therapy. There is evidence from clinical trials in very young children that, of
course, wheezing in young children doesn’t respond to standard therapy as effectively as
in older subjects. There must be reasons behind that which need more research. There
have been increasing doubts about the role of atopy – house-dust mite sensitivity or
bronchial responsiveness – in wheezing in very young children, unlike older asthmatics.
There are lots of reasons for splitting and evidence that there are different subsets.
Cough has been mentioned, and I am not going to go into that, but again that has
suffered the same sort of fate. In the 1980s we had ‘cough variant asthma’ and we were
urged to treat children who coughed at night with antiasthma therapy. It has become
obvious from more detailed studies in the 1990s that children who cough without
wheezing don’t generally have asthma; it’s a different disorder. So there again I think we
have moved on from the stage in the 1970s which was driven by the new therapies, to
be free to begin to think about the different mechanisms of disease – different subclasses,
different phenotypes, different genetic variants – which are contributing to asthma. I
would suggest that this has fed through into adult practice too. Perhaps not as far as it
might (I am not just thinking of chronic bronchitis but of other disorders too) to free
people up and to allow them to begin to explore subsets of asthma and not to think of
it as a single disease, but as a syndrome, the word Donald [Lane] used earlier. 
Godfrey: Thank you very much. I would just like to add a little bit to what Mike
Silverman has said and particularly to pay tribute again to outstanding work done,
epidemiological work in this country, by various people, particularly the study from
Newcastle by Edmund Hey. This was highly original and extremely important. This
was a specific group of babies who had had proven respiratory syncytial virus
bronchiolitis. A marvellous study with a matched control group followed for years.
These little babies looked like little asthmatics, little wheezers, they wheezed their
poor little guts out and they looked just like any other asthmatics, but he showed
clearly that they were not. They had a virus-induced disease that was not asthma,
because what happened was the wheezing gradually petered out over a few months, or
a year or two, and when you looked at these children, I think it was ten years later,
they were quite different from what we normally recognize in asthma. There were very
small differences, if any, between the control group and the asthmatic groups several
years down the line. I think that probably predated Martinez by a long time.171
From the floor: Can I quote you data from the 1960s showing the same thing. John
Fry in 1961 conducted two very carefully carried out studies showing that wheezing
170 Wilson N M. (1989) Wheezy bronchitis revisited. Archives of Diseases in Childhood 64: 1194–1199.
171 Pullan C R, Hey E N. (1982) Wheezing, asthma, and pulmonary dysfunction 10 years after infection with
respiratory syncytial virus in infancy. British Medical Journal 284: 1665–1669.
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in early infancy is a self-limiting disorder.172 There is nothing original about that.
Godfrey: Well, Boesen said that in the 1950s actually,173 if we really are going to go
into a ‘my reference is earlier than your reference’ kind of thing. And it always takes
the Americans a little bit longer to wake up, and basically Martinez is saying the
same sort of thing. Now I know you think that it isn’t specific to respiratory
syncytial virus (RSV), you think it is other viruses do it, and I can’t argue with that,
I haven’t got the information, but we certainly see now a lot of little babies who are
wheezy who do not have asthma, but we do see some little wheezy babies who do
have asthma. Now we have an infant lung function laboratory, we developed the
technology here, originally at the Brompton and then the Hammersmith. We have
the technology for looking at lung function in small infants and for looking at their
response to medication and we see a small proportion of the wheezy babies behave
like asthmatics and I think this is fair, they are asthmatics. In Israel about 10 per
cent of children have asthma, rather less perhaps than here, so I don’t expect more
than 10 per cent of wheezy babies to have asthma. The others don’t have asthma,
they have these virus-associated diseases and they don’t respond to antiasthmatic
medication, which is the important thing. They don’t respond to anything else
either, by the way. 
I would like for us just to remember one other very special person in the history of
childhood asthma in this country and that’s Dick Jones from Liverpool,174 who was
undoubtedly the father of modern exercise-induced asthma, even though Sir John
Floyer described exercise-induced asthma 300 years ago. Dick Jones did some very
beautiful, simple clinical studies, showing that asthmatic children wheezed when they
exercised and he did a lot of studies on the physiology and treatment, and he used
exercise to try to diagnose asthma and to grade its severity. Although Mike [Silverman]
and I and many of us have worked for years and years doing research on exercise-
induced asthma, I really honestly think that we’ve just kind of dotted ‘i’s and crossed
‘t’s and added very, very little to what came out of those studies published in the early
1960s from Liverpool. 
Silverman: I would reinforce that, but I would also like to say that I think Simon
[Godfrey] is being a little bit modest, because he picked up Dick Jones’s idea and ran
with it. I think that you [Simon Godfrey] were actually responsible for developing the
172 Dr John Fry CBE FRCS FRCGP (1922–1994) was in general practice in Beckenham, Kent, from 1947 to
1992, single-handed until 1960. He was a founder member of the Royal College of General Practitioners and a
member of its council for over 30 years.
173 Boesen I. (1953) Asthmatic bronchitis in children. Prognosis for 162 cases, observed 6–11 years. Acta Paediatrica
42: 87–96.
174 Dr Dick Jones was a paediatric cardiologist and respiratory physiologist at the Institute of Child Health, University
of Liverpool, and Alder Hey Children’s Hospital, Liverpool, in the 1960s and 1970s. See Jones R S, Buston M H,
Wharton M J. (1962) The effect of exercise on ventilatory function in the child with asthma. British Journal of Diseases
of the Chest 56: 78–86. Jones R S, Wharton M F, Buston M H. (1963) The place of physical exercise and
bronchodilator drugs in the assessment of the asthmatic child. Archives of Disease in Childhood 38: 539–545.
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real scientific physiology, the exploration of exercise-induced asthma.175 The initial
work took place in the labs at the Brompton Hospital at what was the Cardiothoracic
Institute about 1970 and led to Sandy Anderson’s subsequent work and famous
dispute or duel, with Regis McFadden in the United States about the mechanism of
exercise-induced asthma.176 So I think you are being somewhat modest. I would like
also to say that your comment that I think is also somewhat modest about infant lung
physiology, was another important milestone.177 Another related development at the
Brompton in 1970 was your development and encouragement of measurement of
infant lung physiology using the body box that was derived from work from Kenneth
Cross at the London Hospital,178 and, if I remember, computer programming work in
FORTRAN179 at the Imperial College, but which you developed and which led to a
lot of clinical applications and investigations of pulmonary physiology, and its
applications in infants. I would like you to reflect on what you have been saying about
others, I think you have had an important impact in a number of areas, and those are
just two examples.
Godfrey: I am glad now that I arranged for you to have a free lunch!
Silverman: I will do anything for a free lunch!
Dr Mark Levy:180 Just two anecdotes and a comment related to general practice. I
think it is fair to say that there has been a major change in general practice
management of asthma in the last 20 years and while I accept the criticism that we
may be over-diagnosing asthma, I remember there were two things that patients said
when I first went into practice in the late 1970s, early 1980s. One was that a parent
had contacted the local council to complain and to try to find out why there was an
epidemic of asthma in Northolt, where I was working. I was looking after three streets
of people and there happened to be quite a lot of people in those streets who were
suddenly getting asthma. If you remember the prevalence of asthma at that time was
about 3 per cent and in my practice it was about 11 or 12 per cent, which is a figure
175 See note 90.
176 Anderson S D. (1984) Is there a unifying hypothesis for exercise-induced asthma? Journal of Allergy and Clinical
Immunology 73: 660–665. Anderson S D, Daviskas E, Smith C M. (1989) Exercise-induced asthma: a difference
in opinion regarding the stimulus. Allergy Proceedings 10: 215–226. Anderson S D, Daviskas E. (1992) The airway
microvasculature and exercise-induced asthma. Thorax 47: 748–752.
177 Godfrey S. (1972) The study of physiological responses to exercise in children. MD thesis, University of London.
178 Cross K W. (1949) The respiratory rate and ventilation in the newborn baby. Journal of Physiology 109:
459–474. Godfrey S, Mearns M, Howlett G. (1978) Serial lung function studies in cystic fibrosis in the first five
years of life. Archives of Disease in Childhood 53: 83–85.
179 FORTRAN is an acronym for FORmula TRANslation, the first high-level computer programming language
developed by IBM in the 1950s.
180 Dr Mark Levy FRCGP (b. 1948) has been in general practice since 1977, three-quarter time since March 2001.
He has published original research papers and three books on asthma and in 2000 was appointed Senior Lecturer
(part-time), Department of General Practice and Primary Care, Aberdeen University. He has edited the Primary
Care Respiratory Journal since 1996 and has been Secretary of the General Practice and Primary Care Group of the
European Respiratory Society since 2000. See www.kbmc.org.uk (visited 10 July 2001).
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that Nigel Speight had come out with.181 But the other comment that a patient made
then was, one of my receptionists overheard a patient saying in the waiting room,
‘Whatever you do, don’t tell him that you have got a cough’. Nowadays patients come
in clutching their printouts from the Internet saying, ‘Has my child got asthma?’ So
things have changed a hell of a lot in the last 20 years. 
Godfrey: Thank you very much. 
O’Callaghan: As well as thanking Simon [Godfrey] for being an excellent chairman, I
would like to thank you all for coming and contributing. I have thoroughly enjoyed
myself, limericks and all, and I hope you have.
181 Speight A N, Lee D A, Hey E N. (1983) Underdiagnosis and undertreatment of asthma in childhood. British
Medical Journal 286: 1253–1256.
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